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ABSTRACT 
 
The purpose of the study was to evaluate the IMB skills model for its relevance to the 
Ethiopian context. According to the model, adherence-related information and 
motivation work through adherence-related behavioural skills to affect adherence to 
ART. Quantitative, analytical, observational, cross-sectional, institution-based study was 
conducted to evaluate the model by assessing those patients who have and do not 
have the right information, motivation, and behavioural skills whether they have or do 
not have good adherence to ART. Data was collected using structured questionnaires 
where a total of 400 randomly selected participants provided data on adherence-related 
information, motivation and behavioral skills as well as adherence behavior per se. Data 
was analysed using the Statistical Package for Social Sciences (SPSS) version 20.0. 
 
Both descriptive and inferential statistics used in the study. Only 90.75 % of the total 
sample population reported ART adherence rate of more than or equal to 95% in this 
study. Free and restricted model tests, through bivariate and multivariate analyses, 
used to assess the propositions of the IMB model of ART adherence and provided 
support for the interrelations between the elements proposed by the model. The study 
has supported the applicability of the IMB model of adherence to the Ethiopian context 
highlighting its application in adherence-promotion intervention efforts. The findings 
revealed the need for on-going educational, informational and other interventions to 
address the knowledge, motivation and adherence behavioural skills of patients in order 
to improve the current levels of ART adherence behaviour.  
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1 
CHAPTER 1 
 
ORIENTATION TO THE STUDY 
 
 
1.1 INTRODUCTION 
 
Adherence is the backbone of antiretroviral therapy. Studies of the first antiretroviral 
therapy (ART) showed that almost perfect adherence, classically greater than 95% was 
required to obtain maximal effectiveness (Paterson, Swindells, Mohr, Brester, Vergis, 
Squier, Wagener & Singh 2000:21-30). Never before in medical history has a 
therapeutic regimen required such strict lifetime adherence with serious consequences 
for non-adherence. Sustaining consistent and nearly perfect adherence is required to 
optimise the outcomes of ART, such as minimised drug resistance, slowed disease 
progression, decreased hospitalisation and delayed death and general health, longevity, 
and, quality of life (World Health Organization (WHO) 2013:90). 
 
The success of ART is compromised by failure to maintain optimal levels of adherence 
over the long term and inadequate adherence is the major cause for sub-therapeutic 
drug levels and drug resistance that is transmissible to un-infected or infected others. 
Thus, adherence to therapy has become central and a major concern which requires 
continuous attention to prevent or delay resistance (Ramadhani, Thielman, Landman, 
Ndosi, Gao, Kirchherr, Shah, Shao, Morpeth, McNeill, Shao, Bartlett & Crump 
2007:1492). 
 
Recent reviews suggest that behavioural interventions to promote ART adherence can 
have significant effects. The intervention strategies are various, including one-on-one 
individual or group counselling and education sessions delivered by a clinician or a 
pharmacist, peer group and individual counselling, social and emotional support, 
telephone support such as phone-based counselling, and mobile text messaging, and 
internet-based computerised methods such as electronic pill monitoring as an 
intervention tool (Simoni, Pantalone, Frick & Turner 2010:72). 
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Some use theoretical approaches to guide the development of intervention content, 
mainly drawing from well-known theories of health behaviour changes (such as 
Information, Motivation, Behavioural Skills Model, Trans-theoretical Model, Health Belief 
Model, and others). 
 
In the light of the complexity, dynamicity of human behaviour and a growing urgency in 
understanding the challenges to medication adherence confronting the people with 
Human Immunodeficiency Virus (HIV) in clinical care, developing theory-based 
interventions is essential in promoting an understanding of adherence behaviour.  It can 
be used as a framework for providers of care in facilitating transferability from one 
geographical area or health care setting to another. 
 
One potentially relevant model, the Information-motivation-behavioural skills (IMB) 
model, was first developed in 2001 as a general health model and subsequently was 
tested as a model for ART adherence. Since then it has been repeatedly evaluated and 
finally developed in 2009 as a three-pronged strategy in the United States of America 
(USA) for ART adherence from a meta-analysis perspective. It is comprehensive and 
addresses the cognitive, motivational, and behavioural aspects of change (Medical 
Express 2011; McHorney [S.a.]). The model, however, is characterised by a more 
individualistic approach. The advantage of IMB model is its simplicity and has been 
shown to be moderately effective in promoting behaviour change for ART adherence. 
The model views adherence behaviour as a function of the interrelations between 
adherence-related information, motivation, and behavioural skills. It hypothesises that 
adherence-related information and motivation work through adherence-related 
behavioural skills to affect the initiation and maintenance of optimal ART adherence 
(Munro, Lewin, Swart & Volmink 2007:104). The researcher has selected the model 
because it is the only health model tested and being implemented for intervention for 
ART adherence (Munro et al 2007:104), hence, it has a well-developed tool 
(questionnaire) which can be used for evaluation. 
 
The proposed study aims to evaluate the IMB model and to explore its potential 
application and adaptability on ART adherence in order to determine whether its 
constructs incorporate the patients’ perceived familial and social responsibilities in 
Ethiopian context, where the culture is more collectivist. 
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The proposal presents the following sections: Background to the research problem, 
statement of the research problem, the study framework of the research, purpose of the 
research, research objectives, the research design, significance of the study, limitations 
of the study, and ends with a conclusion. 
 
1.2 BACKGROUND  
 
If the current progress in universal access and scaling up of ART is sustained, the world 
can achieve the global target of 15 million people receiving ART by the end of 2015. 
Most countries with a high burden of HIV infection are potentially on track to achieve the 
universal access based on the 2010 WHO criteria for treatment eligibility (WHO 
2010:19-24; WHO 2013:13). The number of people receiving HIV treatment has tripled 
in the last five years – and reached 9.7 million in low- and middle-income countries in 
2012. That total represents 65% of the global target of 15 million people set for 2015, up 
from 54% at the end of 2011 (WHO 2013:13).  
 
Although the goal of ART is to achieve and sustain viral suppression, drug resistance is 
an inevitable condition which is mainly aggravated by poor adherence to the prescribed 
pills (WHO 2013:11, 90). Multiple factors related to health care delivery systems, the 
medication and the person taking ARV drugs may affect adherence to ART. The 
individual factors include forgetting doses; being away from home; changes in daily 
routines; depression or other illness; a lack of interest or desire to take the medicines; 
and substance or alcohol use. Adherence to ART may also be challenging in the 
absence of supportive environments for people living with HIV and due to HIV-related 
stigma and discrimination (WHO 2013: 80-82). 
 
No single adherence intervention or package of interventions is effective for all 
populations and all settings. People’s needs and circumstances may also change over 
time, and programmes and care providers therefore need to tailor a combination of 
feasible interventions to maximise adherence to ART based on individual barriers and 
opportunities. 
 
Patient education and counselling are an essential package of adherence support both 
when ART is initiated and throughout the course of treatment. Studies (Zeleke & 
 
4 
Thupayagale-Tshweneagae 2013:154; WHO 2013:82) show that counselling improves 
adherence to ART. Informing and encouraging or motivating people receiving ART and 
their families and peers, are essential components of chronic HIV care (WHO 2013:82). 
 
1.3 RESEARCH PROBLEM 
 
Perfect adherence to demanding ART is now recognised as essential for HIV-positive 
patients in order to realise its life sustaining benefits. Adherence success depends on a 
well-established medication taking routine, including health care provider support and 
adequate education on medication changes. Adherence to HIV ART among people 
living with HIV (PLHIV) in developing settings is poorly understood. While many factors 
influence adherence, the literature is dominated by studies on only one or a small set of 
them.  Although substantial progress has been made in recent years in better 
understanding why individuals fail to adhere to ART and have proposed conceptual 
models of ART adherence in resource-rich settings, it is questionable if these social 
cognitive models are well-tested in resource limited settings. This has created a critical 
need to identify factors influencing ART adherence and to develop interventions that 
target such factors. Multivariate, theory-based models of adherence behaviour are of 
greater interest and could help in designing more effective interventions to promote 
treatment adherence (Munro et al 2007:104). 
 
Hence, the evaluation of the transferability of such models is critical in the development 
of effective interventions in resource-poor settings. The current study aims to evaluate 
one such model, which offers a dynamic, multivariate account of ART adherence which 
assumes that adherence-related information, motivation, and behavioural skills are 
fundamental determinants of adherence to ART for its applicability to the Ethiopian 
context where the setting is resource constrained, the culture is collectivist, and the 
health seeking is inclined more to spiritual than biomedical services (Amico, Toro-
Alfonso & Fisher 2005:665). The problem under investigation is that even though the 
IBM model is used its effectiveness is not known within the Ethiopian context.  
 
1.4 RESEARCH PURPOSE 
 
The purpose of the study is to evaluate the IMB skills model for its relevance to the 
Ethiopian context. According to the model, adherence-related information and 
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motivation work through adherence-related behavioural skills to affect adherence to 
ART. Empirical evaluation for the IMB model of adherence will be presented, and if the 
evaluation supports its applicability to the Ethiopian context its application in adherence-
promotion intervention efforts will be discussed. 
 
1.5  RESEARCH OBJECTIVE 
 
1.5.1 General aim  
 
The general aim of this study is to evaluate the Information, Motivation and Behavioural 
Skills (IMB) model of ART adherence in the Ethiopian context, i.e., to determine if the 
assumed or theorised associations between IMB model constructs and adherence in 
resource-rich settings would be applicable for ART patients in the Ethiopian setting. 
 
1.5.2 Specific objectives 
 
In order to achieve the general aim of this study, the following specific objectives were 
set: 
 
 To assess the levels of ART adherence behaviour in patients taking ARV drugs 
at Felege Hiwot hospital which located in Bahir Dar town of the Amhara region of 
Ethiopia. 
 To explore the impact of information about ART and adherence on ART 
adherence behaviour among patients receiving ARV drugs from Felege Hiwot 
hospital. 
 To explore the motivation on ART adherence behaviour among patients receiving 
ARV drugs from Felege Hiwot hospital.  
 To determine behavioural skills needed to practice strict ART adherence on their 
self-reported adherence behaviour of patients at Felege Hiwot hospital ART 
clinic.  
 To assess the benefits of the integration of information, motivation and 
behavioural skills needed to practise strict ART adherence in patients receiving 
ARV drugs from Felege Hiwot hospital. 
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1.5.3 Research questions 
 
Based on the objectives above the study aims to answer the following questions: 
 
 What are the levels of ART adherence behaviour in patients taking ARV drugs? 
 What is the impact of information about ART and ART adherence behaviour 
among patients taking ARV drugs 
 What are the behavioural skills needed to practice strict ART adherence 
 Are they any benefits of the intergration of information, motivation and 
behavioural skills needed to practice strict ART adherence? 
 
1.6 FOUNDATIONS OF THE STUDY 
 
The researcher has used the following IMB skills model of ART adherence adopted 
from previous research to analyse its applicability to the Ethiopian setting. 
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Figure 1.1   IMB model of ART adherence 
 
(Adopted from Amico et al 2005:662) 
 
  
ADHERENCE INFORMATION 
 
 About correct ART utilisation 
and adequate adherence 
 About side-effects and drug 
interactions 
 About heuristic and implicit 
theories concerning adherence 
ADHERENCE BEHAVIOUR 
 
 Proper dosing: percentage of 
ART medications pills taken 
over number prescribed 
 Optimal adherence: 95% or 
greater adherence to dosing 
requirements of all ART 
medications 
 Adherence levels over time 
ADHERENCE MOTIVATION 
 
 Attitudes/beliefs about 
outcomes of adherent and 
non-adherent behaviour and 
evaluation of these outcomes 
 Perceptions of significant 
others’ support for adherence 
and motivation to comply with 
significant others’ wishes 
ADHERENCE MOTIVATION 
 
Objective and perceived 
abilities for: 
 
 Acquiring, self-cueing and 
self-administering ART 
 Incorporating regimen into 
social ecology of daily life 
 Minimising side-effects 
 Updating ART adherence-
related facts as necessary 
 Acquiring social support and 
instrumental support for 
adherence 
 Self-reinforcement of 
adherence over time 
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1.6.1 IBM Model 
 
The IBM model includes three main constructs which are information and knowledge 
about the behaviour; the individual motivation to perform the behaviour and the 
behavioural skills necessary to perform the behaviour (Amico et al 2005:662). 
Adherence information includes relevant knowledge on antiretroviral medications such 
as correct doses, side-effects and drug interactions (Fisher, Fisher, Amico & Harman 
2006b:463). The manner in which information is given can either impede or facilitate 
adherence. On the other hand adherence motivation includes both personal and social 
spheres of motivation. Personal motivations refers to the willingness or non-willingness 
of an individual towards taking ARV drugs, it also means the individual perceptions on 
the benefits of taking drugs. Social support makes for social motivations.  For those 
patients that believe they have enough social support for adherence will probably 
adhere to drugs. The last construct refers to the individual’s ability and willingness to do 
all the necessary skills that would improve adherence (Amico et al 2005:666-669). 
 
1.7 DEFINITION OF KEY CONCEPTS 
 
Information: The Oxford Advanced Learner’s Dictionary (1995:611) defines information 
as “facts told, heard or discovered about something/somebody”.  
 
In this study, information refers to the facts about antiretroviral (ARV) drugs adherence 
and their relative importance for the purposes of this study.  
 
Motivation: The Oxford Advanced Learner’s Dictionary (1995:758) defines motivation 
as “the reason for somebody’s action” or the reason why someone acts as they do.  
 
In this study, motivation refers to the personal and social driver that some people have 
to adhere to the dosage requirements of ART.  
 
Behaviour: The Oxford Advanced Learner’s Dictionary (1995:96) defines behaviour as 
a way in which someone acts or reacts “in the specified way”.  
 
ART is the regimen that is made up of, at least, three antiretroviral drugs (ARV) that is 
potent enough to suppress viral replication and prevent the emergence of resistance for 
a significant period of time. Such regimens have been associated with immunologic 
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restoration, slower HIV clinical progression, durable therapeutic responses, 
improvements in quality of life, and reduction in the emergence of drug resistance 
(African Network for the Care of Children Affected by HIV/AIDS (ANECCA) 2011:155-
156). 
 
ART adherence means the ability of the person living with HIV to be involved in 
choosing, starting, managing and maintaining a given ART regimen to control HIV 
(Human Immunodeficiency Virus) replication and improve the immune function. It 
means taking the correct doses of drugs at the correct time and in the correct way (such 
as with the right type of food or fluid) and sticking to the treatment plan.  It also means 
looking after drugs to make sure they are safe and effective to use. Adherence is 
different from compliance in that the latter is not based upon shared decision-making 
between the patient and provider (Horizons … 2004:16).   
 
Non-adherence to ART includes the following: Missing a dose or doses of ARVs; 
stopping medicine for a day or days; taking the medicines at the wrong time, and taking 
the medicines without dietary instructions (Horizons … 2004:17).  
 
Level of adherence/Adherence behaviour means the percentage of prescribed doses 
swallowed by the patient following instructions given by the provider (conceptual 
definition) (Horizons … 2004:17).  
 
1.8 SIGNIFICANCE OF THE STUDY 
 
Studies in South Africa and Thailand favour the IMB model with complementary 
recommendation of psychosocial support and with modification of the motivation 
construct of the IMB respectively (Peltzer, Preez, Ramlagan & Anderson 2010:3; 
Rongkavilit, Naar-King, Kaljee, Panthong, Koken,Bunupuradah & Parsons 2010:787). 
However, studies conducted to assess the transferability and adaptability of the health 
behaviour models including the model of interest to resource-poor settings are still 
scarce.  It remains to be seen whether this model has general applicability to resource 
constrained settings where health care service and culture is more spiritual than 
biomedical and social, economic and logistical factors, including the accessibility and 
quality of health care services may primarily impact adherence, rather than individual 
client-centred factors. Results from the study will help policy-makers and health 
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managers to make decisions on whether to adopt and apply, modify or adapt the model 
as framework for enhanced adherence intervention. The results of this study will also 
influence curriculum development in training institutions and also stimulate further 
research by researchers.  
 
1.9 ETHICAL CONSIDERATIONS 
 
Researchers, contends that there are important ethical issues which should be taken 
cognisance of while undertaking research (Parahoo 2006:111 & Streubert-Speziale & 
Carpenter 2007:62).  Researchers are indebted to observe certain ethics, in order to 
generally safeguard participants’ rights. 
 
1.9.1 Institutional Review Board 
 
The study was carried out after obtaining ethical clearance from the UNISA Higher 
Degrees Committee (Annexure A).  
 
1.9.2 Permissions 
 
Research Ethics Committees were set up to assess the ethical implications of studies 
which can otherwise be unknowingly detrimental to the lives of research participants. 
The code of ethics and its guidelines are concerned with the protection of human rights 
violations in research involving human subjects. For this study a letter of cooperation 
from Amhara Regional Health Bureau Research and Technology Transfer Process was 
requested and data was collected after receiving written authority from the office of the 
Chief Executive Officer (CEO) of the study hospital (Annexures B and C). The hospital 
CEO was assured that the study would not pose any risk to the participants and that the 
result of the study would be disseminated to the hospital for utilisation.  
 
1.9.3 Informed consent 
 
Informed verbal consent of participants was sought, granted and recorded in writing 
(Annexure D). The objectives of the study were discussed with each participant who 
were briefed that participation in the study has no incentive but has benefits in the long 
run and also that it does not carry any risk. Participants were also informed that they 
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have full right to discontinue the questioning at any time during the session. All those 
who participated in the study signed a consent form (Annexure D). 
 
1.9.4 Privacy and confidentiality 
 
The right to respect of individuals privacy is an international norm that is strongly 
emphasised in research. It is the foundation for building appropriate interpersonal 
relationships among people (Gastmans 1998:26).  Confidentiality is used synonymously 
with concealment or secrecy and in research it is understood to mean that any identity 
of a participant should not be exposed. Any information collected from participants 
should exclude their names and only shared anonymously with other researchers or 
significant others such as policy makers. 
 
Confidentiality and the protection from invasion of privacy were key in this study. The 
interviews were conducted in a private room to ensure privacy and confidentiality.  No 
names were used in the interviewing forms and codes were used instead of names. All 
forms with information about the participants are stored separately from the completed 
questionnaires and in secure storage. 
 
 Privacy and confidentiality will be maintained during and after the interview. The cell 
phone address of the researcher was given to the participants for in case they need 
clarity on any issue regarding the study. The researcher never received any calls from 
participants.  
 
1.10 OPERATIONAL DEFINITIONS 
 
For the purpose of this study adherence behaviour/level of adherence will be defined 
as follows: 
 
 Asking the patient skipped doses or delayed doses for more than two hours over 
the last 3 days, and calculating the adherence rate by the following formula:  
Number of doses taken/Number of doses supposed to be taken for 3 days x 
100% ART adherence level is said to be“ Good” if >95%. Patients will be asked 
about missed doses in the last 72 hours. Assessment will be done by counting 
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how many dose/s s/he missed (taking also delayed doses for ≥2 hours as 
missed) in the previous 3 days.  
 A patient will be labelled as adherent if she or he took all doses in the previous 3 
days, and non-adherent if s/he skipped or took with delay of ≥2 hours even a 
single dose in the previous 3 days. This is based on the above formula and 
considering GOOD (≥95%) or near to perfect adherence necessary for ART. 
 
Adherence behavioural skill in this study refers to the act of taking of ARV drugs in 
compliance with the prescription of the health care worker who administers them. It is 
the perceived as well as objective ability to self-administer ARV medications as noted in 
the conceptual model of the study (operational definition). 
 
1.11 ORGANISATION OF THE THESIS 
 
The thesis is divided into the following chapters:  
 
Chapter 1: Introduction and background information  
 
Chapter 2: Literature review  
 
Chapter 3: Research methodology  
 
Chapter 4: Results and discussion  
 
Chapter 5: Conclusions, strategies, limitations and recommendations  
 
1.12 CONCLUSION 
 
This introductory chapter provided an overview of the study. It includes an introduction 
to the chapter, background information on adherence and ART as used in Ethiopia. The 
chapter also gave an overview of the research problem, significance of the study, 
purpose of the study and objectives of the study. Research questions were also 
included. The chapter concludes by providing the structure for the study.  
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CHAPTER 2 
 
LITERATURE REVIEW 
 
 
2.1 INTRODUCTION 
 
Chapter 2 begins with the background, and then provides an overview of the range of 
social-psychological models, theories and principles. In addition, the chapter provides a 
detailed discussion of the key considerations, limitations and strengths when using 
behavioural models to design interventions. The chapter ends with conclusion. 
 
2.2 BACKGROUND 
 
The current standard of HIV-clinical care in Ethiopia recommends one clinical 
examination every two months and CD4 determination every six months for 
asymptomatic patients responding to treatment (Federal HIV/AIDS Prevention and 
Control Office 2008:6-18). However, gaining an in-depth understanding of the core 
facilitators and barriers to self-sustained retention in HIV care is desperately needed to 
inform effective intervention efforts. 
 
There is an urgent demand in health education and health behaviour science to 
facilitate behaviour changes. According to the Position Paper on Health Education 
prepared jointly by the International Union for Health Education and the Division of the 
Health Education, WHO, Geneva, with the support from the Centres for Disease 
Control, USA (WHO 1992:3) health education is a "combination of planned social 
actions and learning experiences designed to enable people to gain control over the 
determinants of health and health behaviours, and the conditions that affect their health 
status and the health status of others. Health education is therefore, "any combination 
of learning experiences designed to facilitate voluntary actions conducive to health. The 
word “combination” in the definition of health education emphasises the importance of 
matching the multiple determinants of behaviour with multiple learning experiences or 
education interventions; while “designed” distinguishes health education from incidental 
learning experiences as a systematically planned activity. The word “facilitate” means 
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predispose, enable, and reinforce. “Voluntary” means without coercion and with full 
understanding and acceptance of the purposes of the action; and “actions” means 
behavioural steps taken by an individual, group, or community to achieve an intended 
health effect or to build their capacity for health" (Green & Kreuter 1999:190; WHO 
2012:16).  
 
Very often, health promotion as a term is associated with health education. In 1984, the 
WHO defined health promotion as "a process of enabling people to increase control 
over and to improve their health” (WHO 1984:65). Labont’e and Little (Donev, 
Pavlekovic & Kragelj 2007:8-9) defined health promotion as “any activity or programme 
designed to improve social and environmental living conditions such that people’s 
experience of well-being is increased“ Therefore, health promotion is not just the 
responsibility of the individual or  the health sector, but goes beyond healthy life-styles 
to well-being and demands coordinated action and inter-sectoral collaboration.  
 
Historically, there has been a shift from health education to health promotion. The aim 
of health education in its early days was to make people aware of the health 
consequences of their behaviour. People were considered as “empty vessels” that 
process information in a logical manner and subsequently act accordingly. Changes in 
individual opinion attitudes and behaviours were seen to result from information and 
knowledge. The line of thought was that if you provide people with knowledge, they 
could make good decisions regarding their health. In the 1970s the insight grew that 
providing knowledge alone was not enough. To be able to live a healthy life, individual 
motivation, skills and the influence of the social environment were recognised as very 
important determinants as well. People also have to be encouraged, educated, trained 
and facilitated to be able to improve their health and change the environment they live 
in. In addition it has become recognised that individuals cannot be isolated from their 
social environment and that a single behaviour cannot be isolated from the context. The 
approach of the health professionals changed from an educational into a more health 
promotional one (Donev et al 2007:6). 
 
Health behaviour has been defined as “those personal attributes such as beliefs, 
expectations, motives, values, perceptions, and other cognitive elements; personality 
characteristics, including affective and emotional states and traits; and overt behaviour 
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patterns, actions, and habits that relate to health maintenance, to health restoration, and 
to health improvement” (Gochman1997:5). 
 
In the broadest sense, health behaviour refers to the actions of individuals, groups, and 
organisations, as well as their determinants, correlates, and consequences, including 
social change, policy development and implementation, improved coping skills, and 
enhanced quality of life (Glanz, Rimer & Viswanath 2008:12). There are specific 
categories of overt health behaviour embraced in the broader definition of health 
behaviour (Glanz et al 2008:12) including: 
 
(i) Preventive health behaviour: any activity undertaken by an individual who 
believes him/herself to be healthy, for the purpose of preventing or detecting 
illness in an asymptomatic state. 
(ii) Illness behaviour: any activity undertaken by an individual who perceives herself 
or himself to be ill, to define the state of health, and to discover a suitable 
remedy. 
(iii) Sick-role behaviour: any activity undertaken by an individual who considers being 
ill, for the purpose of getting well. It includes receiving treatment from medical 
providers. Generally, it involves a whole range of dependent behaviours, and 
leads to some degree of exemption from one’s usual responsibilities. 
 
“Health Behavioural Science” is an interdisciplinary science which aims to (Pan 2014): 
 
 Understand and describe the nature of human behaviour 
 Investigate the relationship between behaviour and health 
 Find out the barriers and facilitators which influence behaviour 
 Strengthen the theoretical background of health behaviour 
 Develop the behavioural modification techniques 
 Formulate the health intervention or education plan 
 Evaluate the effectiveness of intervention strategies  
 
Where professionals once might have seen their roles as working at a particular level of 
intervention or employing a specific type of behaviour change strategy, there is now 
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increased recognition that multiple interventions at multiple levels are often needed to 
initiate and sustain behaviour change more effectively (Glanz et al 2008:4). 
 
There are many tools and strategies developed to address behaviour change. 
Systematic reviews have shown that designing interventions grounded in theory can 
lead to more fruitful effects than interventions developed without theory. A better 
understanding of the role theories play in producing effective, sustained behaviour 
change is necessary because the theories transform the tools and strategies from one 
that is primarily local and country-specific to one that is both global and local, in a way 
that we increasingly see the world as interconnected (Glanz et al 2008:4). 
 
In the twentieth century, theoretical and practical advances in psychology have helped 
lay the foundation for contemporary important and areas of interest in personality, 
social, clinical, and health psychology. As a microcosm of both psychology and the 
interdisciplinary endeavour of behavioural medicine, these developments have taken 
the position that biological, psychological, and social factors are implicated in all stages 
of health and illness, and the bio-psycho-social model is a guiding framework for the 
application of both psychological theory and research to health, illness, and health care. 
 
Much of the strongest work involved provides theoretical and conceptual frameworks 
that constitute major contributions inasmuch as they are often lacking in traditional 
medicine and medical practice. In this context, it becomes essential to consider such 
distinct theoretical ideas and models as (Donev et al 2007:488). 
 
(a) Psychodynamic conceptions 
 
Psychodynamic theories have gained widespread acceptance and are deeply 
entrenched in the public view of human behaviour. These conceptions of human nature 
commonly view human behaviour as motivated from within by various needs, drives, 
impulses, and instincts. Thought refers to acts of reasoning, reflection, imagining, and 
other personal activities. Psychological methods are evaluated in terms of their 
effectiveness in changing actual psychological functioning (Donev et al 2007:489). 
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(b) Trait theory 
 
Trait theorists are concerned with how dispositions generate behaviour, motivate and 
guide it as well as with assessing personality traits and testing their predictive utility. 
Recent research developments suggest specific models of personality-disease 
relationships. Among these are the investigating the role of Type A behaviour syndrome 
in the aetiology of coronary heart disease, and the potentially protective role of positive 
emotional states and coping styles in the development of illness (Donev et al 2007:490). 
 
(c) Rotter’s social learning theory 
 
The theory infers that behaviour is a function of expectancy and reinforcement value in 
a specific situation. Training in mature decision making, healthy behaviour, coping with 
stress and other life skills is of great importance (Donev et al 2007:490-495). 
 
(d) Bandura’s social cognitive theory 
 
The theory accords a central role to the mechanisms through which the individual 
operates: cognitive processes, motivational processes, affective processes, selection 
processes, and the power of forethought to override feedback control. Self-monitoring, 
self-regulation, including appropriate goal-setting, self-efficacy, and self-control 
mechanisms are described as effective and productive cognitive coping strategies 
(Bandura 1997:126; Bandura 2000:11-27; Donev et al 2007:489). 
 
(e) Creativity in everyday life 
 
Recent research suggests that individuals that use to understand and control events in 
their lives include the creation of new original ways to act upon the environment and 
their life conditions. They engage in the creative process as they construe their world, 
plan their activities, and regulate their behaviour within some reality constraints. 
Creativity involves awareness of context and the flexibility of thinking that can lead a 
person to the creation of multiple perspectives and new ways of looking at things 
(Donev et al 2007:490). 
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The most frequent causes of mortality and morbidity globally are chronic diseases, 
including HIV, heart disease, cancer, lung diseases, and diabetes. Behavioural factors, 
such as sexual behaviour, medication non-adherence, tobacco use, diet and activity 
patterns, alcohol consumption, and avoidable injuries are among the most prominent 
contributors to mortality. Projections of the global burden of disease for the next two 
decades include among others a dramatic rise in deaths from HIV. Worldwide, the major 
causes of death by 2030 are expected to be HIV, depressive disorders, and heart 
disease (Glanz et al 2008:6).  
 
In the advent of ART, the reason why mortality continues from HIV is mainly due to non-
adherence behaviour to prescribed medication which results in treatment failure 
because when patients take their medications irregularly the virus is exposed to 
inadequate (sub-inhibitory) concentrations of antiretroviral medication. This in turn leads 
to on-going viral replication and to the development of resistance to antiretroviral 
medication which accounts for a large portion of treatment failures. Hence, there is a 
critical need to design interventions to improve adherence rate.  
 
Despite the recognised need for targeted need interventions to improve retention in 
care, the literature exploring factors influencing retention in HIV care is largely 
dominated by the identification of demographic correlates of retention. Such correlates 
suggest poorer retention is more likely to occur in people living with HIV (PLWH) who 
are: younger, single, female, those with history of substance use or active current use 
and those with lower socio economic status (SES) (e.g. lower educational attainment, 
lower income, and lack of insurance). Poor retention is also associated with structural 
factors (e.g. unstable housing, greater distances to health facilities) (Volberding, Sande, 
Greene, Lange, Gallant & Walsh 2008:209).  
 
More recent efforts have sought to identify individual-level factors that may be more 
amenable to behavioural change efforts (e.g. health beliefs, acceptance of HIV status 
and abilities to overcome practical barriers to care. Identification of discrete correlates, 
particularly those that are in fact malleable, is critical in building behavioural models that 
more comprehensively attend to the underlying dynamics of sustained retention in HIV 
care, which can be understood as self-directed health promotion behaviour. Even if not 
fundamentally causal, changes in health knowledge and attitudes can contribute to 
individual and population behaviour changes over time (Fishbein 1998:175). There is 
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evidence that health-behaviour change (HBC) interventions in fields such as smoking 
cessation, exercise, diet and HIV risk control have reduced mortality and morbidity from 
conditions such as lung cancer, chronic obstructive pulmonary disease (COPD), 
cardiovascular disease (CVD) and acquired-immune deficiency syndrome (AIDS) 
(Fishbein 1998:176; Fishbein & Pequegnat 2000:101). But the specific part played by 
psychological model use in achieving such health outcomes is uncertain.  
 
Several comprehensive models of health behaviour adoption and maintenance have 
been applied individually and as a system level approach to accessing HIV care, 
including: Anderson’s Behavioural Model of Health Service Utilization, the Chronic Care 
Disease Model, the Health Belief Model, and the Socio-ecological Framework. 
However, models that provide both a good characterisation of underlying determinants 
of retention in HIV care and lead to actionable intervention approaches are lacking. 
There are still relatively few rigorous evaluations of interventions to promote adherence 
to ART and tuberculosis (TB) treatment (Simoni, Frick, Pantalone & Turner 2003:3; 
Volmink & Garner 2006:16); even fewer have explicitly utilised behaviour change 
theories. For example, a systematic review of interventions to promote adherence to TB 
treatment (Volmink & Garner 2006:16) included ten trials, none of which used an explicit 
theoretical framework. A similar review identified seven different randomised controlled 
trials of interventions to promote adherence to ART (Simoni et al 2010), of which only 
one employed an explicit theoretical framework. The researcher cannot therefore 
suggest that these theories be used routinely to design adherence promoting 
interventions. However, since these theories may well have practical behaviour change 
potential, and since the problem of medication adherence remains significant for both 
clinical medicine and public health, further exploratory and explanatory research is 
needed (Munro et al 2007:104). 
 
Given the insufficient amount of evidence to support any particular health behaviour 
theory and partly in response to this gap in literature, Amico and colleagues (Amico et al 
2005:1210) proposed an application and extension of the Information, Motivation, 
Behavioural Skills (IMB) model as an explanatory model of initiation and maintenance in 
clinical care for chronic medical conditions that has immediate application for retention-
related intervention approaches. Thus, the current study uses the IMB model, to test its 
constructs for predicting ART adherence. 
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2.3 THE INFORMATION-MOTIVATION-BEHAVIOURAL SKILLS MODEL 
 
According to Munro et al (2007:104), health behaviour theories may be useful for 
assessing adherence and for developing practical interventions that will promote an 
optimal adherence to ART. From the various health behaviour theories that were 
available, the researcher selected the Information-Motivation-Behavioural skill (IMB) 
model of adherence in order to assess rates of adherence in a particular sample prior to 
designing and implementing a remedial intervention (Fisher et al 2006b:462; Amico, 
Barta, Konkle-Parker, Fisher, Cornman, Shuper & Fisher 2009:73).  
 
2.3.1 The origin and development of IMB model of adherence to ART 
 
The IMB model was initially used in efforts that were targeted at reducing the incidence 
of AIDS-risk behaviour, and the study undertaken by Fisher, Fisher, Misovich, Kimble 
and Malloy (1996:120) showed that after an intervention that made use of the IMB 
model, participants showed significant increments in their personal AIDS-risk preventive 
behaviour. With antecedents in both the health sciences and in social psychology, the 
IMB model conceptualises adherence to ART as a health-related behaviour. The IMB 
model is determined mainly by the extent of an individual’s knowledge of ART, the 
serious consequences of non-adherence, by personal attitudes toward the taking of 
ARV medications (personal motivation), and by the ability to perform whatever 
adherence-related tasks are necessary, together with a strong sense of self-efficacy 
(behavioural skills) (Ware, Wyatt & Bangsberg 2006:19). According to the model, 
information and motivation make a direct as well as an indirect impact on adherence 
behaviour; directly information and motivation can help the individual to acquire an 
optimal adherence behaviour and indirectly they impact on adherence behaviour 
through adherence behavioural skills because information and motivation are 
determinant factors for one to develop and use behavioural skills (Ware et al 2006:19) 
(see figure 1.1). In the light of this, the following three points are considered to be of 
primary importance in the IMB model: 
 
 Information about adherence  
 Motivations for adherence  
 Behavioural skills that facilitate adherence  
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2.3.2 Core assumptions of and statements about the IMB model  
 
The IMB model assumes that adherence-related information, motivation, and 
behavioural skills are fundamental determinants of adherence to ART as well as a wide 
range of useful health-related behaviours. The model asserts that people who are well-
informed and motivated to act and those who possess the behavioural skills to do so, 
are far more likely to adhere to the ART regimen than those who lack these qualities 
and skills. The reverse is also true. A poorly informed person who lacks the motivation 
to act and those who lack the behavioural skills to act effectively, will be less likely to 
adhere to the requirements of the ART regimen (Fisher et al 2006b:463).  
 
The univariate characteristics of the IMB model consider that a direct relation exists 
between adherence behaviour and adherence information, adherence motivation and 
adherence behavioural skills while the multivariate assumptions of the IMB model assert 
that ART adherence information and motivation generally manifest themselves in ART 
adherence behavioural skills in a way that affects adherence behaviour. This is 
especially true if sophisticated skills are a precondition for taking the ARV medications 
(Fisher et al 2006b:466).  
 
The present practice is for patients who are involved with ART to take one fixed-dose 
combination (FDC). This simplifies their lives because they are required to take only one 
tablet in the morning and one tablet in the evening (Federal HIV/AIDS Prevention and 
Control Office (HAPCO) 2008:61). This in itself reveals that no complex behavioural 
skills are required for patients who wish to adhere optimally to their medication. In such 
cases, adherence information and motivation will mainly exert a direct effect on 
adherence behaviour in addition to an indirect effect on behavioural skills (Amico et al 
2005:664; Fisher et al 2006b:464; Starace, Massa, Mariniello, Amico & Fisher 
2006:155; Amico et al 2009:67). It is for this reason that this study assessed the 
univariate correlation of the IMB model constructs (ART adherence-related information 
and motivation and behavioural skill elements) to the levels of adherence for prescribed 
ARV medications.  
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2.3.3  Applications of the IMB model  
 
The IMB model of adherence to ART can be used to understand, predict and promote 
adherence to ARV regimens and to propose a set of operations for designing, 
implementing and evaluating ART adherence promotion interventions. The IMB model 
can also be used to assess a wide range of health-related behaviours with information, 
motivation and behavioural skills as fundamental determinants of behaviour (Fisher et al 
2006b:463).  
 
2.3.4 Components of the IMB model when it is applied to adherence to ART  
 
The components of the IMB model which are displayed in the conceptual framework of 
the current study in chapter 1 (refer to figure 1.1) are information, motivation, 
behavioural skills, and adherence behaviour. Each component is discussed below in 
detail in light of evidence from previous quantitative and qualitative works on the IMB 
model of adherence behaviour to HIV medication as well as retention in HIV care. 
Accordingly, the following concepts are identified and discussed: 
 
 Adherence-relevant information and heuristics 
 Adherence-relevant motivation which refers to a personal and social motivation to 
follow one’s ART regimen as prescribed 
 Adherence-relevant behavioural skills which comprise an individual’s objective 
abilities and perceived self-efficacy to enact a series of coordinated behaviours 
involved in the execution of the adherence behaviour 
 Adherence behaviour per se 
 
(i) Information 
 
The first determinant of an IMB model, information, reflects objective information (and 
misinformation) held by an individual regarding the specific health behaviour in 
question. The information construct also contains cognitive heuristic or implicit theories 
held by an individual such as health beliefs specific to HIV that are often used to guide 
health behaviours (e.g. absence of AIDS symptoms means one does not need medical 
care). The heuristic process is used as a simple decision rule permitting the individual to 
make decisions (often incorrect ones) about engaging or not engaging in the specific 
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health behaviour. The use of inaccurate heuristics typically occurs without recognition of 
the cognitive process associated with the behavioural decision in question (Fisher, 
Cornman, Osborn, Amico, Fisher & Friedland 2004:S78; Fisher & Fisher 1992:455).  
 
The specific kinds of objective information(and misinformation)  relevant to adherence 
include basic accurate information about the regimen, requirements of adherence, drug 
interactions and side-effects, information on the disease itself (HIV/AIDS), including the 
process of adjusting life with HIV and changes in the disease course; and information 
about the available system(s) of care and support such as information about available 
treatment(s), their purpose and typical procedures, including interrelated ancillary 
services available to facilitate access to and use of HIV treatment (e.g. case 
management) and patients’ rights to receive the services (Fisher et al 2006b:462; 
Fisher, Amico, Fisher & Harman 2008:193; Amico 2011:1071). 
 
(ii) Motivation 
 
Motivation to engage in the health behaviour is the second component in the IMB 
model, impacting on individuals’ inclination to act on what they know about the 
behaviour. Motivation is comprised of an individual’s personal motivation (i.e., attitudes 
and beliefs about engaging or not engaging in the behaviour), as well as his or her 
social motivation (i.e., perceptions of social norms regarding the appropriateness of the 
behaviour and of the social support or social consequences for engaging in the 
behaviour; Fisher & Fisher 1992:457; Fisher et al 2004:S80).  
 
Amico (2011:1072) states that the specific kinds of personal motivation identified in the 
situated application of the IMB model as critical to adherence to HIV medication( and 
retention in HIV care) include the attitudes and beliefs about the positive and negative 
consequences of adherence to HIV medication in terms of (1) prioritising self-care in the 
face of competing priorities, (2) obtaining results of viral load, CD4 monitoring and 
disease progression, (3) managing negative feelings related to living with HIV such as 
HIV stigma, acceptance of diagnosis or the long term effects of HIV, and HIV 
treatment). Social norms and degree of support for navigating care are reflected in 
social motivation in terms of (1) degree of perceived social support for adhering to 
medication from important others (including navigating HIV stigma or cultural beliefs 
about the relevance of adherence to HIV medication); (2) perceptions of patient-provider 
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interactions including anticipated consequences of disclosing substance use or non-
adherence to HIV medication; (3) resilience against social pressures and norms to 
prioritise adherence to HIV medication. 
 
Motivation-related correlates identified in the literature and anticipated to be of 
relevance to patients’ experiences of adherence behaviour  in the current study reflect: 
personal motivation which includes one’s  attitudes and beliefs about outcomes of 
adherent and non-adherent  behaviour and evaluation of these outcomes (Beer, Fagan, 
Valverde & Bertolli 2009:785-792), perceived vulnerability (including subjective health 
status) to the positive consequences of adherence or negative consequences of non-
adherence (Gordon, McGinnis, Conigliaro, RodriguezBarradas, Rabeneck & Justice 
2006:S37), trust in one’s provider and the health care system (Beer et al 2009), and 
attitudes towards living with HIV (e.g., HIV-stigma and acceptance of diagnosis; Beer et 
al 2009:790).  
 
In addition to personal motivation, social motivation refers to factors such as perceived 
social norms and social support for adherence as well as one’s motivation to comply 
with their wishes, perceived engagement of one’s provider in patient-provider 
interactions (Bakken, Holzemer & Brown 2000:189; Cunningham, Sohler, Korin, Gao & 
Anastos 2007:226), and the presence of personal external support systems (e.g., 
family, friends, mental health treatment, transportation and other support services 
(Bodenlos, Grothe, Whitehead, Konkle-Parker, Jones & Brantley 2007:65; 
Cunningham,et al 2007:228; Rajabiun, Mallinson, McCoy, Coleman, Drainoni, Rebholz 
& Holbert 2007:S20) for accessing care and adhering to HIV medication over time. 
 
(iii) Behavioural skills 
 
Behavioural skills for engaging in the health behaviour is the third critical component of 
the IMB model, and comprises an individual’s objective abilities and perceived self-
efficacy to enact a series of coordinated behaviours involved in the execution of the 
health behaviour, per se (Fisher et al 2004; Fisher & Fisher 1992). The specific kinds of 
behavioural skills identified in the situated application of the IMB model as critical to 
adherence to HIV medication (Amico 2011:1078) include objective skills and perceived 
self-efficacy across three distinct skill sets for systems navigation, overcoming practical 
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barriers to adherence to HIV medication, and enhancing sustained optimal adherence to 
medication over time.  
 
Systems navigation skills: These set of skills reflect perceived and actual abilities to 
access available HIV care and arrange resources for adherence to medication 
(including navigation of ancillary care services to aid in adherence to HIV medication).  
 
Functional skills (organising/planning): Are used to overcome practical barriers to 
medication adherence, such as skills to integrate HIV medication in regular part of one’s 
daily life when one is too busy to take the medication or when the daily routine deviates, 
such as long distance travel (including use of reminder strategies) and arranging to 
attend care visits to refill medication (including transportation) in the context of 
competing demands and barriers, such as employment, child care, and  more pressing 
comorbidities, such as active substance use or depression.  
 
Activation skills: Reflect intend to minimise perceived negative consequences of 
medication adherence and maximise perceived positive consequences of medication 
adherence and refill important for sustaining adherence over time (i.e., skills to 
increase/maintain HIV health literacy, invest in affective adjustment to HIV diagnosis 
and long term outcomes, seek instrumental and emotional social support for medication 
adherence and medication refill appointments regularly, and sustain prioritisation of self-
care in the face of competing demands and barriers such as mental health issues, 
substance use, and housing instability. 
 
Correlates reflecting such behavioural skills noted in previous work and anticipated to 
be present across patients’ experiences of adherence to HIV medication in the current 
study include: perceived and objective ability to overcome perceived and practical 
barriers to adherence to medication and appointment (e.g. transportation, competing 
priorities, and mental health issues) (Rajabuin et al 2007:S22), ability to access support 
services (e.g., case management, mental health treatment) (Cunningham et al 
2007:226; Tobias, Cunningham, Cunningham & Pounds 2007:8), as well as the ability 
to negotiate care in the context of living with HIV (e.g., coping with diagnosis, 
maintaining a sense of ‘normalcy’, HIV stigma) and other comorbidities (e.g., substance 
use, depression) (Rajabuin et al 2007:S24). 
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Adherence behaviour: Adherence behaviour is the cumulative percent of medication 
that a patient has taken from the number of drugs that have been prescribed for that 
patient. This can be calculated as the number of doses that a patient has taken over the 
total number that were prescribed during a specific time period (Amico et al 2005:665). 
The adherent behaviour of individuals to ART can be divided into two modes: optimal 
adherence is practised by those who took 95% or more of their dosing requirements 
while sub-optimal adherence is practised by those who took less than 95% of the 
dosages that were prescribed for them during the prescribed period (Fisher et al 
2006b:468; Glass, Geest, Weber, Vernazza, Rickenbach, Furrer, Bernasconi, 
Cavassini, Hirschel, Battegay & Bucher 2006:386; Amico et al 2009:67; Amberbir, 
Woldemichael, Getachew, Girma & Deribe 2008:4).  
 
2.3.5  Modifying factors of the IMB model relationship  
 
Practical adherence barriers such as inadequate or difficult access to medical care can 
affect the relationship between information, motivation and behavioural skills and 
adherence behaviour (Fisher et al 2006b:463; Amico et al 2009:67). This means that 
patients with no perceptual adherence barriers may not adhere if they have barriers 
related to capacity and resources. Fisher et al (2006b:462) suggests that in such cases 
the moderator variables can operate through the core IMB model constructs and the 
intervention would address information regarding the interaction of ARVs and for 
instance hazardous drinking, and motivational barriers and behavioural skills specific to 
unintentional non-adherence which is related to practical barriers. Some of the 
moderating factors affecting adherence without the intention of the patient are (Fisher et 
al 2006b:268):  
 
 Poor access to medical care and services( e.g. shortage of medication supplies, 
distance, and lack of insurance coverage) 
 Unstable living situation 
 Substance use or addiction 
 Psychological health( e.g. depression) 
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2.3.6 Summary of the components of the IMB model  
 
The IMB model of adherence addresses information about adherence and the 
motivation to maintain adherence that includes personal and social motivations and the 
necessary behavioural skills for adhering to ART. It also considers situational and 
individual characteristics such as the ease or difficulty of access to medical care that 
can affect the relationship between IMB model constructs and adherence behaviour 
(Amico et al 2009:67).  
 
2.3.7 Critique of the IMB model 
 
The Information-Motivation-Behavioural Skills (IMB) model of ART adherence offers a 
systematic framework for theory-based interventions (Fisher et al 2006b:3; Fisher et al 
2008:193). The model has received support from previous research with other 
populations on ART and has been the basis for a number of different adherence 
interventions (Amico, Konkle-Parker, Cornman, Barta, Ferrer, Norton, Fisher 
2007:1210; Amico et al 2009:66; Amico et al 2005:661; Fisher et al 2008, Smith 2011). 
It has been previously used in risk behaviour interventions in young people (Fisher et al 
1996), in investigating challenges of ART adherence in HIV-positive youth (Rongkavilit 
et al 2010), and ART-related views in youth at risk of HIV infection (Simon, Altice, Moll, 
Shange & Friedland 2010:464). 
 
The Information-Motivation-Behavioural Skills (IMB) model of ART adherence offers a 
systematic framework for theory-based interventions (Fisher et al 2006b:4; Fisher et al 
2008:195). The model has received support from previous research with other 
populations on ART and has been the basis for a number of different adherence 
interventions (Amico et al 2005:662; Amico et al 2007:1212; Amico et al 2009:67; Fisher 
et al 2008:194; Smith 2011:S205). It has been previously used in risk behaviour 
interventions in young people (Fisher et al 1996:), in investigating challenges of ART 
adherence in HIV-positive youth (Rongkavilit et al 2010:790), and ART-related views in 
youth at risk of HIV infection (Simon et al 2010:463). 
 
However, the model is not without limitations and it has specific limitations when it is 
applied to ART adherence as well as general limitations that it shares with any health 
behaviour model. According to Darnton (2008:19-20), the IMB model has the following 
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limitations which are generally shared by other behavioural models used as frameworks 
for developing interventions: 
 
 Models are concepts, not representations of behaviour: they show the factors 
influencing behaviour, but do not explain the processes for changing behaviour. 
 Behaviour is complex, but models are deliberately simple: they are concepts to 
aid understanding – they are deliberately simplistic and do not capture all the 
factors that account for behavioural outcomes. 
 There is a limit to how far models will stretch:  they are developed in the context 
of a specific behaviour, and tend to work best in that context – although some do 
have wider applicability. 
 Models don’t tend to differentiate between people: they tend to show the 
behaviour of a statistical ‘everyman’ – and need to be adapted in order to cover 
different audience groups. 
 Factors don’t always precede behaviour:  most behavioural models present 
social-psychological factors as preceding behaviour but there are instances 
where people are compelled to change their behaviour first, which then lead to 
change in the social-psychological variables. 
 Factors are not barriers: behavioural models can appear to present factors as 
buttons to be pressed, in the expectation that the behavioural outcome shown 
will result. This is a misleading interpretation, not only because other factors 
which are ‘off the model’ may also need to be accounted for, but because the 
mechanistic assumptions underpinning such a view are inadequate to explain the 
nature of change, and to support individuals in that process. 
 The review of theories of change also identifies a number of procedural limits to 
using behavioural models in aiming to bring about behaviour change. At a basic 
level, theories of change stress that interventions must look beyond the individual 
to address the context within which they function (their ‘social fi eld’, or ’system of 
interest’). Procedurally, the principles of action research as deployed in diverse 
methods show that engaging actors in the process is the best way to bring about 
change amongst them. In addition, systems thinking approaches have put 
forward fundamental objections to interventions based on models. Systems 
thinking can best be understood as a discipline for understanding complex 
problems; the process of analysing the problem itself reveals opportunities for 
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interventions. Systems thinking thus offer an approach based on modelling 
complex behaviours, rather than advocating the use of existing models.  
 
While the above generic limitations hold true in varied degree to the IMB model, it also 
has a few specific limitations when it is applied to ART adherence which are directly 
related to the questionnaire and not to the model as such. The suggested LW-IMB-AAQ 
contains sets of ART adherence information, motivation, and behavioural skills items 
which remain the same despite they are being used in different settings and cultures. 
For example, the behavioural skills that are required to take on time and store drugs 
may not be difficult for those living at home, while they may be difficult for those who live 
in prison; individuals who are in prison may need to exercise highly sophisticated 
behavioural skills to cope with the stigma and discrimination that emanate from the 
institution. This then represents a challenge to use the proposed questionnaire 
unanimously (Fisher et al 2006b:465).  It is, however, important to note that the 
measure is not intended for use as a comprehensive or generic measure of the IMB 
model of adherence constructs. According to Fisher et al (2006a:4), that the Life 
Windows Project Team preliminary analyses suggest that the LW-IMB-AAQ does 
provide an overview of adherence related barriers that generally fall within information, 
motivation, and behavioural skills areas, and can be used as a tool to quickly identify 
potential adherence related deficits in practical or real-world settings. The measure and 
its psychometric properties will be evaluated over the course of the Life Windows 
Project.  
 
2.3.8  Summary of the components of the IMB model  
 
The IMB model of adherence addresses information about adherence and the 
motivation to maintain adherence that includes personal and social motivations and the 
necessary behavioural skills for adhering to ART. It also considers situational and 
individual characteristics such as the ease or difficult access to medical care that can 
affect the relationship between IMB model constructs and adherence behaviour (Amico 
et al 2009:67).  
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2.4 CONCLUSION 
 
There is currently an emerging understanding of attitudes and norms in shaping 
adherence behaviour to HIV medication. Policy makers and health managers have 
recognised that poor adherence has dire consequences and that though many factors 
contribute to poor adherence, changing individual adherence behaviour is often central 
to the solution. However, there is no simple solution to the subject of behaviour change 
required for adherence. Health behaviour theories may throw light on the processes 
underlying behaviour change to improve ART adherence. However, a ‘single-variable’, 
predictive approach is not always effective for a successful intervention and further 
examination is needed to determine whether theory based interventions in health care 
are more effective than those without an explicit theoretical foundation. To understand 
and overcome the barriers to treatment adherence, considerable further research is 
needed.  
 
The current review contributes to advancing the field of HIV medication adherence 
behaviour by paying a special attention on the information, motivation, and behavioural 
skills model of ART adherence which is the focus of the study. The review gives an 
intensive description of the IMB model of ART adherence, presenting the evidence and 
critique for it and discussing applicability of the model to ART adherence behaviour in 
the study setting.  In doing so, the review aims to evaluate the utility and validity of 
applying the IMB model to a new behavioural and sociocultural setting (i.e., PLWH on 
ART in chronic HIV care clinic at Felege Hiwot referral hospital located in Bahir Dar 
town, Ethiopia); identifying the types of theoretical content (i.e., types of information, 
motivation, and behavioural skills) underlying adherence to ART to address in future 
intervention development for this target population. 
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CHAPTER 3 
 
RESEARCH DESIGN AND METHODOLOGY 
 
 
3.1 INTRODUCTION 
 
This chapter outlines and elaborates on the methodological aspects and processes 
which were used to evaluation of the impact of information-motivation-behavioural skills 
model of adherence to antiretroviral therapy in Ethiopia.Aspects of the methodological 
issues such as research design, sampling, data collection methods and analysis used, 
validity of the data and ethical considerations undertaken during the research will be 
discussed. 
 
Four main topics are discussed: 
 
 research design 
 sampling 
 methods of data collection  
 methods of data analysis 
 
As part of data analysis, issues around internal and external validity of data were 
considered. Lastly, the summary of the chapter is given. 
 
3.2 RESEARCH DESIGN 
 
A research design is a blueprint for conducting the study that maximises control over 
factors that could interfere with the validity of the findings (Burns & Grove 2013:195).  
Quantitative design will be adopted for this study.  Stommel and Wills (2004:3) refers to 
quantitative research as “the systematic development of new knowledge via a process 
of assembling empirical evidence”, and Burns and Grove (2013:54) point out that 
quantitative studies seek to describe variables, investigate relationships among 
variables, and determine cause and effect relationships between variables. 
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3.2.1 Rationale for choosing a quantitative cross-sectional design 
 
Study design refers to the structured approach followed by researchers to answer a 
particular research question (Joubert & Ehrlich 2007:77). This study will be a 
quantitative, analytical, observational, cross-sectional, institution-based study. A cross-
sectional study is the simplest variety of descriptive or observational epidemiology that 
can be conducted on representative samples of a population. It is used as a useful way 
to gather information. Like cohort and case-control studies, the goal of analytical cross-
sectional study is to examine the relationship between an exposure and an outcome. 
Unlike cohort and case-control studies, however, a cross-sectional study does not 
assess and compare occurrence of incident cases in two groups, rather, it assesses 
and compares the prevalence of exposure or outcome across the two groups (Joubert & 
Ehrlich 2007:84).  This characteristic of cross-sectional study makes it a preferable 
design for conducting this study because the researcher has time pressure, and 
resources and financial constraints to conduct a study. 
 
3.3 RESEARCH METHODOLOGY 
 
Research methodology refers to the practices and techniques use to sample the 
population size and how data was processed and analysed (Vaus 2001:143). According 
to Khothari (2004:7), a research methodology may be defined as academia’s 
established framework for the collection and evaluation of existent knowledge for the 
purpose of arriving at, and validating new knowledge. Also the importance of research 
methodology emanates from its definition of activities of a specified research, its 
procedural methods, strategies for project measurements and criteria for research 
success (Kothari 2004:7). 
 
3.3.1 Study setting and period 
 
Ethiopia is a low-income country in East Africa, with a total population of 73.8 million 
according to the 2007 population and housing census (Central Statistical Agency (CSA) 
2012:3). The overall adult HIV prevalence in Ethiopia has remained low and according 
to the 2011 Ethiopian Demographic and Health Survey (EDHS 2011), the HIV 
prevalence among adults aged 15 to 49 is 1.5% and women have a higher HIV 
prevalence (1.9%) as compared to 1.0% among men.  For both women and men the 
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HIV prevalence increases substantially as the number of lifetime sexual partners 
increases (CSA 2012:234).  
 
This study was conducted at one of the public referral hospitals in Amhara regional 
state, located in Bahir Dar town. The hospital is 55 years old with a catchment 
population of 7 million people in 2014. The hospital has a total of 800 staff including 14 
general practitioners, 10 general surgeons, 4 gynaecologists, 4 internists, 3 
paediatricians, 1 orthopaedic surgeon, 1 ophthalmologist, 1 urologist, 4 radiologist, 1 
dermatologist, and 4 psychiatric specialists. It has an outpatient department and, 
obstetrics and gynaecology, chronic care, surgery, ophthalmologic, psychiatric, 
orthopaedic, ICU, pharmacy, emergency, inpatient serving, paediatrics, physiotherapy 
unit, and central laboratory units, and a blood bank. The hospital has its own ART team 
and a clinic led by a physician, nurses, health officers, laboratory technicians, data 
clerks, case managers and adherence counsellors.  
 
The hospital provides general outpatient and in-patient services, including surgical and 
obstetric emergency care. Infectious diseases account for most of the inpatient and out-
patient visits. The hospital has been providing voluntary counselling and testing (VCT) 
services for more than a decade and provider initiated testing and counselling (PITC) 
services for the past 8 years. Free ART services were started in January 2006. 
According to the 2011 EDHS (CSA 2012:235), the adult HIV prevalence among women 
and men aged 15 to 49 who were tested in the Amhara region was 1.6%.The study 
period was six weeks between 1st September and 12 October 2014. 
 
Below is the map of Ethiopia and the study site, Felege Hiwot hospital is located in 
Bahir Dar town. 
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         (Bahir Dar) 
 
Figure 3.1   Map of Ethiopia 
(Source World Atlas) 
 
Below are the pictures of the ART clinic at Felege Hiwot hospital. The pictures show the 
hind and front views of the ART clinic located inside the hospital compound. 
 
Figure 3.2   Felege Hiwot hospital ART clinic 
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3.3.2 Sampling, sampling procedure, sample size and the population and sample 
selection 
 
3.3.2.1 Sampling 
 
Sampling involves selecting a group of people, events, behaviours or other elements 
from a larger population or universe, with which to conduct a study. The objective of 
sampling is to determine mathematically the most effective way of acquiring a group of 
participants that would accurately reflect the population under study. A probability 
sampling plan better ensures precision in the accurate estimation of the population 
parameters, thus reducing sampling errors (Burns & Grove 2013:357). For the current 
study, a sampling procedure was designed to ensure representation of the study 
population. 
 
3.3.2.2 Sampling procedure 
 
The concept of systematic sampling was applied in this study when selecting 
participants for the structured interviews. Systematic sampling refers to selecting, from a 
population list or “sampling frame,” every kth individual, using a starting point selected 
randomly. The population size is divided by the desired sample size, giving k, the size of 
the gap between elements selected from the list. For this study, Felege Hiwot referral 
hospital was selected conveniently as it is the most nearby hospital with adequate 
population size. The participants were only included if they fulfilled the criteria, i.e. 
patients who are 15 years of age and older and who have been on ART for a period of 
12 months or more. These participants were recruited when they came into the clinic to 
collect their medication or had doctors’ appointments by using systematic random 
sampling.  
 
The sampling frame (adult appointment calendar/logbook) contains names of patients 
on ART who were expected to attend the health facility in the time period decided to 
collect data. The sampling frame contains all the patients on ART and each patient is 
given an appointment for follow-ups every month. 
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Using systematic random sampling, the first participant was selected randomly. Then, 
each 6fh individual attending an appointment at the ART clinic was included in the study. 
 
3.3.2.3 Sample size 
 
Patients meeting the inclusion criteria were selected until the required sample size was 
obtained. The sampling interval is: K=Sampling frame (N)/Sample size (n)=5785/400 
=14.4≈14.The starting participant was selected randomly and every 14th person on the 
list was included in the sample. The health facility, Felege Hiwot referral hospital, where 
the study was carried out, at the time of the data collection had 5785 registered patients 
who were on ART. 
 
The sample was determined using the single population proportion formula as 
described by Le (2003:452). The assumptions are that the sample is representative; the 
sampling error is small, the sample is viable in the context of funds available for the 
research study, systematic bias is controlled in a better way and results from the sample 
study will be generalisable. 
 
Assuming a random sampling and a normal distribution, a response rate of 90%, 50% 
for anticipated proportion and a significance level of 0.05, the sample size needed was 
calculated using the formula below:   
 
𝑛𝑜=
𝑧2𝑝(1−𝑝)
𝑑2
 
Where, 
p= anticipated population proportion (50%, since there is no previous study 
done) 
d=the precision required on either side of the proportion (=0.05) 
z=the cut-off value of the Normal distribution (=1.96 at level of significance 
of 0.05) 
𝑛𝑜=
𝑧2𝑝(1−𝑝)
𝑑2
=
1.9620.5(1−0.5)
(0.05)2
=384.16=384, since sampling is from a finite 
population of N=5785(Adults > 14 years of age currently on ART in the 
hospital ART clinic).      
n=
𝑛𝑜
1+
𝑛𝑜
𝑁
= 
384
1+
384
5785
=360.09=360 
For a response rate of 90%,    𝑛𝑓=
360
0.9
   =400, where 𝒏𝒇=the final sample 
size. 
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3.3.2.4 Population and sample selection 
 
The study/target population in this study included all PLWH who are currently on ART at 
the HIV care clinic, Felege Hiwot hospital in Bahir Dar. PLWH aged 15 years and above 
who were started on and receiving ART for at least 12 months at the time of data 
collection were included in the study.  
 
3.3.2.4.1 Inclusion criteria 
 
The participants had to be outpatients at least 15 years of age, able to give informed 
consent, and not seriously sick, and had been taking ART for a minimum of one year 
because studying a trend of an individual’s ART adherence requires to set adequate 
time period in which the researcher can capture both the immediate issues or barriers of 
adherence like pills side-effects as well as maintenance challenges in adherence 
behaviour.   
 
3.3.2.4.2  Exclusion criteria 
 
Those patients on 2nd line regimen after treatment failure, and those on short-course 
ART for prophylaxis (PEP (Post-Exposure-Prophylaxis) and PMTCT (Prevention of 
Mother-to-Child Transmission of HIV)) were excluded from the study because the 
purpose of the study was to investigate adherence in chronic care, those clients 
receiving ART for life long and the study was not intended to evaluate short-term 
adherence.  
 
3.3.3 Ethical issues related to sampling 
 
The age of consent in Ethiopia is 15 years old and above. The study complied with 
national requirements (Federal MOH and Federal HAPCO 2007:4) which require that 
study participants can consent from the age of 15. The ethical protection of the 
respondents was maintained throughout this study.  The following ethical principles 
were adhered to: 
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3.3.3.1 Informed consent 
 
Informed consent is viewed as a process by which the researcher and a potential study 
participant communicate about the goals, benefits, and risks of the research. Informing 
is the transmission of essential ideas and content from the investigator to the 
prospective subject. Consent is the prospective subject’s agreement to participate in a 
study or subject, which is reached after assimilation of essential information. 
 
The goal of informed consent is to allow the person to make an informed decision about 
whether to participate in the research. Procedures about informed consent should 
support the intent of the three key ethical principles (beneficence, respect of persons, 
justice). Informed consent is an important mechanism to ensure that people have the 
rights to: 
 
 Remain free from harm and undue exploitation 
 Receive any benefits to which they are entitled as a result of research 
participation 
 Receive fair treatment that ensures the protection of personal privacy 
 Be fully informed of the risks associated with research participation 
 Freely decide whether to participate or to continue to participate in research at 
any time, without forfeiture of benefits to which they would otherwise be entitled 
(Stommel & Wills 2004:387-388). 
 
Informed consent requires the researcher to disclose specific information to each 
prospective subject. The following information has been identified as essential content 
for informed consent in research:  
 
 Introduction of research activities 
 Description of risks and discomforts 
 Description of benefits 
 Disclosure of alternatives 
 Assurance of anonymity and confidentiality 
 Compensation for participation in research 
 Offer to answer questions 
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 Non-coercive disclaimer 
 Option to withdraw 
 Consent to incomplete disclosure 
 
Informed consent implies not only the imparting of information by the researcher but 
also the comprehension of that information by the subject. Thus, the consent 
information must be written and verbalised in lay terminology, not professional jargon, 
and must be presented without the use of loaded or biased terms that might coerce a 
subject into participating in a study. Most studies require a written consent form, 
although in some studies, the consent form is waived. The documentation of informed 
consent depends on (i) the level of risk involved in the study and (ii) the discretion of the 
researcher and those reviewing the study for institutional approval (Burns & Grove 
2005:195-196). 
 
Informed verbal consent of participants was sought and recorded in writing. The 
objectives of the study were discussed with each participant. The cell phone number of 
the principal investigator will be given to the participants for any queries. All this 
information will be given both orally and in written leaflet to each participant.  
 
3.3.3.2 Risk and discomfort 
 
The participants were told that the study had no risks or discomfort except that 
answering questions would take a maximum of 30 minutes to avoid participants feeling 
like their time is being wasted and that they had full right to discontinue the questioning 
at any time during the session.  
 
3.3.3.3 Benefits 
 
Participants were told that their participation in the study might not give them direct 
benefits or incentives, but that it would enable the researcher to identify barriers and 
facilitators of adherence to ART, which subsequently could be utilised by the relevant 
health care workers to provide evidence-informed and appropriate ART adherence 
counselling and support based on the study. 
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3.3.3.4 Anonymity and confidentiality 
 
Anonymous data collection means that the researchers have no way to link the 
identifying information for study participants with the data provided. In contrast, 
confidential data collection means that the researcher potentially or actually can link the 
identifying information for study participants with the data. In this situation, the 
researcher must provide assurances, including specific information about the methods 
used to safeguard confidentiality, to the study participants (Stommel & Wills 2004:382-
383).   
 
The information that we collected from this research project was kept both anonymous 
and confidential.  Information was stored in a file, which does not have names of 
respondents on it, but a code number assigned to it. Which number belongs to which 
name is kept secret. 
 
3.3.3.5 Right to refuse or withdraw 
 
Participants were told that they had full right to refuse to participate in the research (they 
could choose not to respond to some or all questions). It was further explained to the 
participants that if they did not wish to participate in the study it would not affect the 
treatment or health care that they get from the health facility in any way. Participants 
were also told that they had the full right to withdraw from the interview at any time they 
wished to, without losing any of their rights as clients in this health institution. 
 
3.3.4 Data collection 
 
The most important purpose of any research is to collect information the researcher can 
use to synthesise and analyse in order to find meaning from large raw information which 
can be generalised into a summary of a phenomenon. Burns and Grove (2011:52) 
explain that data gathering is the precise, systematic collection of information relevant to 
research problems using appropriate design and methods. In this study data was 
collected in line with the objectives of the study. 
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3.3.4.1 Data collection approach and method 
 
Quantitative data were collected by asking questions (self-report). Face-to-face exit 
interview was selected as the preferred mode of administration of the written 
questionnaire as it is personal (one-on-one) setting. ART outpatients at point-of-HIV-
care services were the sources of data. 
 
3.3.4.2 Development and testing of the data collection instrument 
 
The Life Windows version of Information-Motivation-Behavioural Skills ART Adherence 
Questionnaire (LW-IMB-AAQ) adopted from the University of Connecticut, Centre for 
Health, Intervention, and Prevention (Fisher, Amico, Cornman & Fisher 2006a) was 
used to collect data from the participants. A short questionnaire was also prepared by 
the researcher to assess level of adherence (Annexure E). 
 
The questionnaire was translated into Amharic, a local language used in the city. The 
items were translated by the principal investigator and back-translated by another skilful 
interpreter. The translation and back translation was done to ensure that participants 
would understand and comprehend the purpose, methods, and risks and benefits 
related to the study before consenting to participate in the study.  
 
3.3.4.3 Characteristics of the data collection instrument 
 
The LW-IMB-AAQ contains sets of ART adherence information, motivation, and 
behavioural skills items. It is a structured questionnaire composed of closed-ended 
questions that have options with five response categories with response choices 
addressing agreement. The agreement options include statements such as I strongly 
disagree, I somewhat disagree, I neither agree nor disagree, I somewhat agree, and I 
strongly agree. It is the recognised standard questionnaire to collect quantitative data to 
evaluate the validity and utility of the IMB model in a specific setting; it contains sets of 
ART adherence information, motivation, and behavioural skills items that assess the 
impact or applicability of the IMB model to address the information needs as well as the 
motivation and the behavioural skills that are necessary for investigating adherence to 
ART (Fisher et al 2006a). 
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The LW-IMB-AAQ was developed within the Life Windows adherence intervention 
software programme, a computer-delivered ART adherence intervention for the purpose 
of assessing barriers to antiretroviral therapy (ART) adherence among HIV+ patients in 
clinical care (Fisher, Fisher, Amico & Harman 2006b).  
 
The LW-IMB-AAQ provides the Life Windows intervention programme with critical 
information about users’ ART adherence-related strengths and weaknesses. The 
software programme uses that information to determine which specific intervention 
activities would be most relevant to a user given his or her specific constellation of 
adherence-related barriers. The user is then offered this targeted set of intervention 
activities and asked to select an activity that would be most helpful in improving or 
maintaining his or her ART adherence. Thus, each LW-IMB-AAQ item serves a dual 
purpose: quantifying information, motivation, and/or behavioural skills strengths and 
weaknesses, and signalling which specific IMB adherence-related deficits should be 
addressed in order for adherence to improve or most effectively be maintained. 
 
In developing the LW-IMB-AAQ items, item content was a target specifically to reflect 
barriers within the information, motivation, and behavioural skills constructs pertinent to 
the population involved. It is likely; however, that the barriers reflected in the LW-IMB-
AAQ would generalise across many HIV+ populations. Nonetheless, any application of 
this measure outside of the Life Windows project should take into consideration 
 
(a)  The purpose for which the measure was developed — quantification of IMB 
based adherence-related deficits so as to direct participants to available 
intervention activities and  
 
(b)  The target population for whom it was developed — HIV+ men and women in 
clinical care. It is also important to note that the measure is not intended for use 
as a comprehensive or generic measure of the IMB model of adherence 
constructs. Preliminary analyses suggest that the LW-IMB-AAQ does provide an 
overview of adherence related barriers that generally fall within information, 
motivation, and behavioural skills areas, and can be used as a tool to quickly 
identify potential adherence related deficits in practical or real-world settings. The 
measure and its psychometric properties will be evaluated over the course of the 
Life Windows project. 
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3.3.4.4 Data collection process 
 
Data were collected by one medical doctor (who was the supervisor) and four trained 
nurses on basic ART. The nurses were not employees of the hospital. This was done in 
order to free participants from possible fear of judgment by the staff during subsequent 
visits. Training was given on data collection techniques, and there was close 
supervision during data collection process. All collected data was assessed daily by the 
supervisor for its completeness for implementation of early correctional measures for 
the following day activities.   
 
Data were collected for six weeks in order to obtain the desired population according to 
the sampling method selected, as every ART patient is appointed every one month for 
refill and reassessment. The daily patient flow according to appointment was found to 
range from 120 (over the weekends) to 260 clients (in week days). Assuming this and 
participating every 14th client seven days a week (as the ART clinic is open in the 
weekends though the client is less by half) attains the calculated sample size. The two 
weeks were added to capture those who came days after the appointment date 
because of different reasons. 
 
3.3.4.5 Data measurement  
 
Adherence-related information was measured by nine behaviourally relevant knowledge 
items using a five point Likert scale as ‘I strongly disagree’, ‘I somewhat disagree’, ‘I 
neither agree nor disagree’, ‘ I somewhat agree’ or ‘I strongly agree’ to show the effect 
on the dependent construct were rated by the participants. These items are presented 
in the information construct of the IMB model (figure 1.1).  
 
(i) Knowledge of information 
 
The responses to the nine items on the knowledge about what to do if one misses a 
dose of any of HIV medications (e.g., whether or not to take the pill(s) later)’; how 
substance use (Khat, marijuana) could affect the way HIV pills work and what the side-
effects of the combination therapy medication might be were scored as correct 
response “2 =strongly agree and “1”=/unsure and/incorrect responses.  
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From the responses, the researcher then created two groups to represent participants 
who were well-informed and those who were not. Since the median in the sample falls 
between four and five points, the researcher defined those well-informed as having 
scored five or more, and those less well-informed as having scored four or less than 
four.  
 
(ii) Adherence related motivation 
 
Adherence-related motivation was also measured according to the IMB model (figure 
1.1). Participants used a five point Likert scale to respond to each of the ten items 
designed to assess aspects of adherence related motivation (M1, M2, M3, M4, M5, M6, 
M7, M8, M9, M10). Similarly, ‘attitudes about ART and ART adherence’ (e.g., It upsets 
me that the HIV medications I have been prescribed can cause side-effects) were 
assessed and rated very good or “1” if the response was ‘I strongly disagree’. The 
responses were rated very bad or “0” if the response was ‘I somewhat disagree’. In 
addition, the ‘perceptions of significant others’ support for ART adherence’ (e.g., ‘Most 
people who are important to me who know I am HIV positive support me in taking my 
HIV medications’) was assessed.  The responses were rated “1” for (‘I strongly agree’ 
and ‘I somewhat agree’). Item responses were then summed and compared with the 
median after the item reflecting success (M4) was reverse scored. Total motivation 
scores ranged from zero to ten, where ten represents higher motivation. Whether the 
patient has good motivation or not was decided by taking the median as a cut-off point. 
Those respondents with six and above out of ten were decided to have good motivation 
and those with five and below were decided to have poor motivation.  
 
(iii) Behavioural skills 
 
In the IMB model, adherence related behavioural skills are represented by fourteen 
behaviourally relevant items that represent the diverse set of skills required for 
adequate ART adherence. The Items include assessments of the participants’ skills for 
taking medication as prescribed in the presence of a number of barriers including (‘How 
hard or easy is it for you to stay informed about HIV treatment?’, ‘How hard or easy is it 
for you to get the support you need from others for taking your HIV medications (e.g., 
from friends, family, doctor, or pharmacist)?’‘How hard or easy is it for you to take your 
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HIV medications when you are wrapped up in what you are doing?’,  ‘ How hard or easy 
is it for you to manage the side-effects of your HIV medications?’, ‘How hard or easy is it 
for you to make your HIV medications part of your daily life?’, ‘How hard or easy is it for 
you to take your HIV medications when your usual routine changes( e.g., when you 
travel or when you go out with your friends? ’). 
 
Participants were rated according to the extent to which they agree or disagree with 
each statement on a five-point scale. The scoring gave “1” for ‘easy’ and ‘very easy’ and 
“0” for the ‘very hard’, ‘hard’, ‘sometimes hard, and sometimes easy’ responses. All B 
labelled items were summed to represent a total behavioural skills score. Out of 14 
items or responses, if a respondent scored 8 and above ‘easy’/ ‘very easy’ responses or 
‘somewhat agree’ / ‘strongly agree’ in the case of B1 they were considered having good 
behavioural skills and those with 7 and below easy/very easy responses were decided 
as having poor or inadequate behavioural skills important to adhere to ART. 
 
B1 appears to behave differently and does not share significant variability with the other 
behavioural skills items. B1 may be more valuable as an indicator of a barrier and need 
for intervention, but may also prove to be useful in explaining adherence for individuals 
who specifically use alcohol or drugs ( Refer to the study questionnaire: Annexe D). 
 
3.3.4.6 Ethical considerations related to data collection 
 
In order to respect the rights of the institutions where the study was carried out, the 
researcher assured the following before commencement of the study: 
 
 Permission to carry out the research study was obtained from the Higher 
Degrees Committee of the Department of Health Studies at UNISA for ethical 
clearance (Annexure A). 
 Letter of cooperation from Amhara Regional Health Bureau, Research and 
Technology Transfer Process, was requested and data was collected after 
receiving written authority from the office of the Medical Director of the study 
hospital. The hospital management was assured that the study would not pose 
any risk to the participants and that the result of the study would be disseminated 
to the hospital and to the bureau for information and possible utilisation.  
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3.3.5 Data analysis 
 
Data were sorted, coded, and entered into the computer using a Statistical Package for 
Social Sciences (SPSS) software version 20.0. Data was presented using charts, 
graphs and frequency tables.  
 
The IMB model's critical constructs and assumptions were evaluated for its applicability 
in an Ethiopian ART clinic with the following analytical steps: 
 
The analysis of the evaluation of the IMB model constructs’ association with each other 
and with treatment adherence was carried out in two steps: 
 
1. The first step applied binary logistic regression to explore the relation between 
the three constructs and the dependent variable, ART adherence.  
2. The second step applied binary logistic regression to explore the relation 
between each of the three constructs.  
3. The third step involved evaluation of the association between the interaction of 
variables of the three independent constructs (information, motivation, and 
adherence behavioural skills) with ART adherence. The step applied multivariate 
analysis and binary logistic regression. 
 
The magnitude of the association between the variables of the independent constructs, 
in relation to a dependent variable was measured through odds ratios (OR) and their 
95% confidence interval (CI). For comparisons P< 0.05 values were considered 
statistically significant. 
 
3.4 INTERNAL AND EXTERNAL VALIDITY OF THE STUDY 
 
Bowling (1997:180) had suggested that the reliability of data collected during research 
should be tested using internal consistency; a process that usually involves ensuring 
that the questions presented in the questionnaires and interviews could be classified in 
one category. According to Van der Riet and Durrheim (2008:90), a study is said to 
have external validity if the findings can be generalised beyond the confines of the 
design and the study settings. 
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3.4.1 Validity 
 
Polit and Beck (2012:236) state that validity is the approximate truth of an inference and 
it is always a matter of degree, not an absolute; validity is a property of an inference, not 
of a research design, but design elements profoundly affect the inferences that can be 
made.  Validity refers to the conceptual and scientific soundness of a research study. 
There are four distinct types of validity: internal validity, external validity, construct 
validity, and statistical conclusion validity. Internal validity refers to the ability of a 
research design to rule out or make implausible alternative explanations of the results, 
or plausible rival hypotheses. External validity is concerned with the generalisability of 
the results of a research study. In the context of research design and methodology, the 
term construct validity relates to interpreting the basis of the causal relationship, and it 
refers to the congruence between the study’s results and the theoretical underpinnings 
guiding the research. Statistical conclusion validity refers to aspects of quantitative 
evaluation that affect the accuracy of the conclusions drawn from the results of a study 
(Polit & Beck 2012:236; Marczyk, DeMatteo & Festinger 2005:158-197). 
 
In this study validity was assured through the following processes: 
 
(i) The questionnaire: pre-tested questionnaire was adopted from a standardised 
questionnaire  
(ii) Translation of the questionnaire: The questionnaire was applied after translating 
into local language to suit the language ability of participants. 
(iii) Sample size determination:  Adequate sample size was determined and used for 
data collection. 
(iv) Inclusion and exclusion criteria: Strong inclusion and exclusion criteria were used 
(v) Reducing bias:  By using random selection of study subjects from the study 
population, and making the participants/sample population representative of the 
study population, selection bias was prevented in this study. To minimise 
information bias, the study ensured that all variables were measured in the same 
way on all participants.  In this cross-sectional study design, unlike in a case-
control study, the data collectors knew little about the participants which would 
help to additionally prevent information bias in the study. By using rigorous 
inclusion and exclusion criteria and using random selection of study subjects 
from the study population, and making the participants/sample population 
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representative of the study population, selection bias will be prevented in this 
study. Social desirability bias was minimised by being non-judgmental. In 
addition, social desirability and recall biases with reference to medication 
swallowing were avoided by assuming that those participants with optimal 
behavioural skills would have optimal ART adherence.  
(vi) External validity: The source of data is a primary source (at point of service) and 
external validity was maintained.   
 
3.4.2 Reliability 
 
Reliability is concerned with the consistency or stability of the score obtained from a 
measure or assessment over time and across settings or conditions. If the 
measurement is reliable, then there is less chance that the obtained score is due to 
random factors and measurement error (Polit & Beck 2012:231-336; Marczyk et al 
2005:103). 
 
By using an adequate sample size and standard questionnaire, the researcher 
optimised precision of the measurement instruments. Self-report data is the most 
commonly used method for measuring adherence in routine clinic settings because it is 
easy and inexpensive to collect data and can distinguish between the two forms of non-
adherence, that is, intentional and unintentional. However, the approach has some 
drawbacks including tendency to over-estimate adherence, lack of sensitivity and 
specificity and it typically only reflects short-term adherence. Hence, the researcher has 
preferred to use self-report to measure adherence.  
 
3.5 CONCLUSION 
 
Chapter 3 outlined the research methods used to solicit information from participants, 
hence answer the research questions. The population sampling, data collection, 
instrument, ethical considerations, and data analysis were also discussed. Most of the 
topics were defined; the study methodology was viewed and discussed in line with the 
definition given and in line with the objective of the study. Advantages and challenges of 
selected study methods and designs were discussed.  
  
 
49 
CHAPTER 4 
 
PRESENTATION AND DESCRIPTION OF THE RESEARCH FINDINGS 
 
 
4.1 INTRODUCTION 
 
Chapter 3 presented and discussed the research design and the research methods that 
were used in this study. This chapter presents the results that emerged from the data 
analysis. The purpose of this study was to assess levels of adherence to ART and the 
factors that affect it using the IMB model’s proposed set of factors in a randomly 
selected sample of HIV infected patients who were on a regimen of ART at Felege 
Hiwot hospital of the Amhara region of Ethiopia. 
 
In order to meet the purposes of the study the data collection and analysis was guided 
by the following five objectives of the study: 
 
 To assess the levels of ART adherence behaviour in patients taking ARV drugs 
at Felege Hiwot hospital which is located in Bahir Dar town of the Amhara region 
of Ethiopia. 
 To explore the impact of information about ART and adherence on ART 
adherence behaviour among patients receiving ARV drugs from Felege Hiwot 
hospital. 
 To explore the impact of motivation on ART adherence behaviour among 
patients receiving ARV drugs from Felege Hiwot hospital. 
 To determine the impact of adherence behavioural skills needed to practice strict 
ART adherence on their self-reported adherence behaviour of patients at Felege 
hiwot hospital ART clinic. 
 To assess the benefits of the integration of information, motivation and 
behavioural skills needed to practise strict ART adherence in patients receiving 
ARV drugs from Felege Hiwot hospital. 
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4.2  DATA MANAGEMENT AND ANALYSIS 
 
In this study, the data were collected by means of a structured questionnaire that 
consisted of the following four sections:  
 
1.  Adherence information  
2.  Adherence motivation  
3.  Adherence behavioural skills  
4.  Adherence behaviour 
 
The population consisted of HIV/AIDS patients on ART who had been taking ARV 
medication for at least twelve months and who were at least 15 years old at the 
commencement of the study. A sample of 400 respondents was determined from a total 
population of 5785 registered patients who were on ART at the time of data collection. 
The sample was determined using the single population proportion formula.  
 
The data were at all times kept safely and stored in a place to which no one other than 
the researcher had access, and the data was saved and protected on by a secret 
password. 
 
A statistician analysed the data that were collected from all 400 respondents by using a 
Microsoft software package called the Statistical Package for the Social Science 
(SPSS) (version 20). The findings of the study aimed at meeting the study objectives 
and are presented according to the sequence in the questionnaire and are presented 
according to the following sub-headings:  
 
 Information factors 
 Motivation factors 
 Behavioural skills 
 Summary of findings from descriptive statistics 
 Patients reported rates of adherence 
 Overview of research finding findings from inferential statistics 
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Various tables, graphs and descriptions as well as percentages, p-values, and other 
tests are used to present the findings and ends up with a conclusion.  
 
4.3  RESEARCH RESULTS 
 
4.3.1  Information factors 
 
This section assessed how much the respondents knew about adherence to ART. 
 
4.3.1.1 Knowledge of prescription advice 
 
A total of 325 patients claimed that they know how each of their current HIV medication 
is supposed to be taken (for example whether or not their current medication can be 
taken with food, herbal supplements, or other prescription medication) whereas 46 
patients reported that they did not know how each of their HIV medication is supposed 
to be taken. 
 
These figures suggest that the majority knew how to take their ARV medication. In 
contrast to the findings in this study, Starace et al (2006:156) indicated that only 51% of 
their samples were adequately informed about how to adhere to the ART dosage 
schedule, and that 49% demonstrated that they were inadequately informed about how 
to adhere to their ART dosage schedule. In a study carried out by Wang and Wu 
(2007:151), only 75.4% of their patients were able to demonstrate the correct dosage 
schedules for their HIV-prescribed medication. 
 
Table 4.1  Know HIV medicine are supposed to be taken 
 
Description Frequency Percent 
Strongly disagree 45 11.3 
Somewhat disagree 1 0.3 
Neither agree nor disagree 2 0.5 
Somewhat agree 27 6.8 
Strongly agree 325 81.3 
Total 400 100.0 
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4.3.1.2 Knowledge of measures to take for missed doses 
 
A total of 140 patients claimed that they know what to do when they miss a dose of any 
of their HIV medication while 255 patients reported that they don’t know what to do if 
they miss a dose of their HIV medication. These results show that more than 63.8% of 
the respondents were of the opinion that they didn’t know what they should do if they 
had missed a dose(s) of their ARV medication.  
 
Table 4.2 Know what to do if I miss a dose of medication 
 
4.3.1.3 Consequence of skipping a dose 
 
A total of 372 patients agreed that skipping a few of their HIV medication from time to 
time would not really hurt their health, while only 26 patients disagreed. Two patients 
neither agreed nor disagreed. This shows that the majority of patients said it was a 
serious problem to miss doses provided that they felt healthy. A study carried out by 
Golin, Liu, Hays, Miller, Beck, Ickovics, Kaplan & Wenger (2002:759) reported that 77% 
of their respondents did not agree with the statement, “You could fight off HIV without 
medication.” 
 
Table 4.3 Skipping few of my HIV medication will not really hurt my health 
 
Description Frequency Percent 
Strongly disagree 18 4.5 
Somewhat disagree 8 2.0 
Neither agree nor disagree 2 0.5 
Somewhat agree 5 1.3 
Strongly agree 367 91.8 
Total 400 100.0 
 
 
  
Description Frequency Percent 
Strongly disagree 241 60.3 
Somewhat disagree 14 3.5 
Neither agree nor disagree 5 1.3 
Somewhat agree 52 13.0 
Strongly agree 88 22.0 
Total 400 100.0 
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4.3.1.4 Knowledge of side-effects 
 
Three hundred and twenty two patients claim that they know the possible side-effects of 
each of their HIV medicines, while 73 patients reported the opposite. This shows that 
only 18.3% of the population were ignorant of the possible side-effects of their HIV 
medication. 
 
Table 4.4 Know the possible side-effects of my HIV medication 
 
Description Frequency Percent 
Strongly disagree 59 14.8 
Somewhat disagree 14 3.5 
Neither agree nor disagree 4 1.0 
Somewhat agree 79 19.8 
Strongly agree 243 60.8 
Total respondents 399 99.8 
Missing 1 0.3 
Total 400 100.0 
 
4.3.1.5 Knowledge for lifelong medication adherence 
 
Altogether, 373 patients strongly believe that as long as they are feeling healthy, 
missing their HIV medication from time to time is acceptable and only 24 patients 
reported that missing their medication was dangerous. 
 
Table 4.5  As long as feeling healthy missing HIV medication is acceptable 
 
Description Frequency Percent 
Strongly disagree 19 4.8 
Somewhat disagree 5 1.3 
Neither agree nor disagree 3 .8 
Strongly agree 373 93.3 
Total 400 100.0 
 
 
4.3.1.6 Knowledge on medication mechanisms of action  
 
A total of 369 patients reported that they understand how each of their HIV >medicines 
works in their bodies to fight HIV while 27 of them said they did not understand the 
mechanism of action of their HIV medication.  
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Table 4.6 Understand HIV medication works to fight HIV 
 
Description Frequency Percent 
Strongly disagree 20 5.0 
Somewhat disagree 7 1.8 
Neither agree nor disagree 3 0.8 
Somewhat agree 25 6.3 
Strongly agree 344 86.0 
Total respondents 399 99.8 
Missing 1 0.3 
Total  400 100.0 
 
 
4.3.1.7 Knowledge of consequences of interruption of medication 
 
A total of 180 patients agreed that if they did not take their HIV medication as 
prescribed, the medicines may not work for them in the future whereas, 214 patients 
disagreed on this. This means out of the total number of respondents, 45% of the 
respondents said that the medication would not work properly in the future if they 
missed doses from time to time while 53.5% of the respondents said the drugs would 
work properly in the future if they did not take their medication as prescribed. This is a 
lower rate than that reported in the study by Golin et al (2002:759), who reported that 
85% patients agreed that if they did not take their HIV drugs as prescribed; their HIV 
would become resistant to treatment in the future. This rate of responses is also higher 
than that reported in the study undertaken by Wang and Wu (2007:151), who reported 
that 66.3% of their patients believed that non-adherence to ART could lead to the failure 
of the treatment in the future. 
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Table 4.7  If I do not take my HIV medication, the medicine may not work for the 
future 
 
Description Frequency Percent 
Strongly disagree 196 49.0 
Somewhat disagree 18 4.5 
Neither agree nor disagree 5 1.3 
Somewhat agree 80 20.0 
Strongly agree 100 25.0 
Total 399 99.8 
Missing 1 0.3 
Total 400 100.0 
 
4.3.1.8  Knowledge of the benefits of medication adherence  
 
There were 387 patients who believe that if they take their HIV medication as 
prescribed, they will live longer while only 8 patients believe the opposite of this. Two 
patients did not give their answers. This means that 96.8% of respondents have the 
knowledge and belief that the HIV medication will help them fight and control their HIV 
infection to let them live longer. 
 
Table 4.8 If I take my HIV medication, I can live longer 
 
Description Frequency Percent 
Strongly disagree 6 1.5 
Somewhat disagree 2 0.5 
Neither agree nor disagree 3 0.8 
Somewhat agree 12 3.0 
Strongly agree 375 93.8 
Total 398 99.5 
Missing 2 0.5 
Total 400 100.0 
 
4.3.1.9 Knowledge of drug interactions with alcohol and substances 
 
A total of 85.5% of the respondents claimed that they know how their HIV medicines 
interact with alcohol and other substances and 13% of patients reported that they did 
not agree with this idea. Only five respondents said that they neither agree nor disagree 
with interaction of HIV medication with alcohol and other substances. 
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Table 4.9  Know HIV medication interact with alcohol and other substances 
 
Description Frequency Percent 
Strongly disagree 48 12.0 
Somewhat disagree 4 1.0 
Neither agree nor disagree 5 1.3 
Somewhat agree 30 7.5 
Strongly agree 312 78.0 
Total 399 99.8 
Missing 1 0.3 
Total 400 100.0 
 
4.3.2 Motivation factors 
 
This section assessed both the personal and social motivation of respondents to adhere 
to their ARV medication. 
 
4.3.2.1  Secrecy to swallow pills 
 
Out of the total number of respondents, 56.8% strongly agreed, 4% agreed, 0.8% were 
undecided, 19.5% disagreed, and 18.8% strongly disagreed with statement that they 
are worried that other people might realise that they are HIV+ if they see them taking 
their HIV. In a study conducted by Wang and Wu (2007:152), 43.8% claimed that they 
had been treated differently by their neighbours and friends after their neighbours and 
friends knew that they were taking ART. 
 
Table 4.10  Worried HIV+, if people see me taking my HIV medication 
 
Description Frequency Percent 
Strongly disagree 75 18.8 
Somewhat disagree 78 19.5 
Neither agree nor disagree 3 0.8 
Somewhat agree 16 4.0 
Strongly agree 227 56.8 
Total respondents 399 99.8 
Missing 1 0.3 
Total 400 100.0 
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4.3.2.2 Frustration to plan to take medication 
 
Out of the total number of respondents, 70.5% strongly agreed, 2.5% agreed, 0.5% 
were undecided, 13% disagreed, and 13.5% strongly disagreed with the idea that it 
frustrated them to have to plan their lives around their HIV medication. The results 
obtained from the survey showed that more than 88% of the respondents were not 
frustrated by having to plan their lives in such a way that they could accommodate their 
HIV medication in their schedules. 
 
Table 4.11  Frustrated taking HIV medication around my life 
 
Description Frequency Percent 
Strongly disagree 54 13.5 
Somewhat disagree 52 13.0 
Neither agree nor disagree 2 0.5 
Somewhat agree 10 2.5 
Strongly agree 282 70.5 
Total 400 100.0 
 
4.3.2.3  Dislike taking HIV medication because of how it reminds of HIV status 
 
Out of the total number of respondents, 88.8% strongly agreed, 0.5% agreed, 2.3% 
disagreed, and 8.5% strongly disagreed with the statement that they did not like to take 
their HIV medication because it reminded them that they were HIV-positive. The result 
shows that more than 89% of the respondents agreed with the statement that they did 
not like to take their HIV medication because it reminded them that they were HIV-
positive. This shows that acceptance of the diagnosis and resolution to live positively 
with the infection is achieved only by a small proportion of patients. 
 
Table 4.12  Don’t like taking my HIV medication, reminds me that I am HIV+ 
 
Desription Frequency Percent 
Strongly disagree 34 8.5 
Somewhat disagree 9 2.3 
Somewhat agree 2 0.5 
Strongly agree 355 88.8 
Total 400 100.0 
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4.3.2.4  My HCP takes account of needs while selecting ART regimen 
 
Out of the total number of respondents, 65% strongly agreed with the statement, 21.5% 
agreed, 0.5% remained undecided, 4.8% disagreed and 7.8% strongly disagreed with 
the statement that their HCPs take their needs into account when making 
recommendations about which HIV medicine to take.  
 
Table 4.13  Feel that health care provider’s recommendations are client-need-
based 
 
Description Frequency Percent 
Strongly disagree 31 7.8 
Somewhat disagree 19 4.8 
Neither agree nor disagree 2 0.5 
Somewhat agree 86 21.5 
Strongly agree 260 65.0 
Total respondents 398 99.5 
Missing 2 0.5 
Total 400 100.0 
 
 
4.3.2.5 People support to take medication 
 
Out of the total number of respondents, 75.3% strongly agreed with the statement, 
12.5% agreed, 0.5% remained undecided, 1.3% disagreed and 10.3% strongly 
disagreed with the statement that most people who are important to them who know 
they are positive support them in taking their HIV. 
 
Table 4.14  People are important for taking HIV medication 
 
Description Frequency Percent 
Strongly disagree 41 10.3 
Somewhat disagree 5 1.3 
Neither agree nor disagree 2 0.5 
Somewhat agree 50 12.5 
Strongly agree 301 75.3 
Total respondents 399 99.8 
Missing 1 0.3 
Total 400 100.0 
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4.3.2.6 HCP gives inadequate support to take medication 
 
Out of the total number of respondents, 83.3% strongly agreed with the statement, 2.8% 
agreed, 0.5% remained undecided, 6% disagreed and 7.5% strongly disagreed with the 
statement that their health care providers don’t give them enough support when it 
comes to taking their medication as prescribed. 
 
Table 4.15  Health care provider doesn’t give enough support 
 
Description Frequency Percent 
Strongly disagree 30 7.5 
Somewhat disagree 24 6.0 
Neither agree nor disagree 2 0.5 
Somewhat agree 11 2.8 
Strongly agree 333 83.3 
Total 400 100.0 
 
4.3.2.7 Frustration of the thought of taking medication for lifelong 
 
Out of the total number of respondents, 79.5% strongly agreed with the statement, 3.8% 
agreed, 0.5% remained undecided, 6.8% disagreed and 9.5% strongly disagreed with 
the statement that it would frustrate them to think that they would have to take HIV 
medication daily for the rest of their lives. The result shows that the vast majority of the 
respondents said that it frustrates them to think that they will have to take these HIV 
medicines every day for the rest of their lives. 
 
Table 4.16  Frustrating to take HIV medication for life 
 
Description Frequency Percent 
Strongly disagree 38 9.5 
Somewhat disagree 27 6.8 
Neither agree nor disagree 2 0.5 
Somewhat agree 15 3.8 
Strongly agree 318 79.5 
Total 400 100.0 
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4.3.2.8 Worry that the medication hurts health 
 
Out of the total number of respondents, 78.5% strongly agreed with the statement, 3% 
agreed, 0.5% remained undecided, 10.3% disagreed and 7.8% strongly disagreed with 
the statement that they would be worried by the knowledge that the HIV medication that 
were prescribed for them could harm their health. These results indicate that more than 
80% of the respondents were worried about the fact that the HIV medicines that were 
prescribed for them could harm their health. 
 
Table 4.17  Worried HIV medication hurts my health 
 
Description Frequency Percent 
Strongly disagree 31 7.8 
Somewhat disagree 41 10.3 
Neither agree nor disagree 2 0.5 
Somewhat agree 12 3.0 
Strongly agree 314 78.5 
Total 400 100.0 
 
 
4.3.2.9  Concerns that the medication change one’s look 
 
Out of the total number of respondents, 64% strongly agreed with the statement, 1.8% 
agreed, 1.8% remained undecided, 21.5% disagreed, and 11% strongly disagreed with 
the statement that its went upset them think that the HIV medication that had been 
prescribed for them could affect the way they looked. The results shows that at least 
65% of the respondents were upset by the fact that the HIV medication could affect the 
way that they looked. 
 
Table 4.18 I am upset by HIV medication, it affects the way I look 
 
Description Frequency Percent 
Strongly disagree 44 11.0 
Somewhat disagree 86 21.5 
Neither agree nor disagree 7 1.8 
Somewhat agree 7 1.8 
Strongly agree 256 64.0 
Total 400 100.0 
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4.3.2.10 Fear of side-effects 
 
Out of the total number of respondents, 62.3% strongly agreed with the statement, 4% 
agreed, 0.8% remained undecided, 20.5% disagreed, and 12.3% strongly disagreed 
with the statement that they would be upset to think that the prescribed HIV medicine 
could cause side-effects. These responses show that more than 66% of the 
respondents were upset about the side-effects that can be caused by HIV medication. 
 
Table 4.19  I am up upset by HIV medicine, they cause side-effects 
 
Description Frequency Percent 
Strongly disagree 49 12.3 
Somewhat disagree 82 20.5 
Neither agree nor disagree 3 0.8 
Somewhat agree 16 4.0 
Strongly agree 249 62.3 
Total respondents 399 99.8 
Missing 1 0.3 
Total 400 100.0 
 
4.3.3 Behavioural skills 
 
This section assessed the behavioural skills of respondents with regard to ART 
adherence. 
 
4.3.3.1  Difficulty of taking medication with alcohol and substance use 
 
Out of the total number of respondents, 50.5% strongly agreed with the statement, 1% 
agreed, 1.3% remained undecided, 8% disagreed, and 39.3% strongly disagreed with 
the statement that there are times when it is hard for them to take their HIV medication 
when they drink alcohol or use drugs. The data show that more than 50% of the 
respondents witnessed their experience that alcohol and other substances are barriers 
to adherence.  
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Table 4.20  Difficulty in taking HIV medication, while drinking alcohol or using 
drugs 
 
Description Frequency Percent 
Strongly disagree 157 39.3 
Somewhat disagree 32 8.0 
Neither agree nor disagree 5 1.3 
Somewhat agree 4 1.0 
Strongly agree 202 50.5 
Total 400 100.0 
 
4.3.3.2  Difficulty of getting information on HIV treatment 
 
Out of the total number of respondents, 3.8% maintained that it was very hard for them 
to remain well-informed about HIV treatment, 3% reported it was hard, 12.3% were 
undecided, 80.3% said that it was easy for them to remain well-informed, and 0.8% said 
it was very easy for them to remain well-informed about HIV treatment. This means that 
more than 80% of the respondents have the perception that they are able to remain 
well-informed about their HIV treatment. 
 
Table 4.21  informing about HIV treatment 
 
Description Frequency Percent 
Very hard 15 3.8 
Hard 12 3.0 
Sometimes hard 28 7.0 
Sometimes easy 21 5.3 
Easy 321 80.3 
Very Easy 3 0.8 
Total 400 100.0 
 
4.3.3.3  Difficulty in getting support from others 
 
Out of the total number of respondents, 3.5% said it was very hard for them to get the 
support they needed from others in order to take their HIV medication, 1% said that it 
hard, 12.3 said that it was difficult to decide, 81.8% said it was easy for them to get 
support, and 1.5% said that it was very easy for them to get the support they needed 
from others in order to take their HIV medication. This study therefore showed that 
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83.3% of the participants felt that they could get the support they needed from others in 
order to take their HIV medication. 
 
Table 4.22  Get support from others for taking HIV medication 
 
Description Frequency Percent 
Very hard 14 3.5 
Hard 4 1.0 
Sometimes hard 35 8.8 
Sometimes easy 14 3.5 
Easy 327 81.8 
Very Easy 6 1.5 
Total 400 100.0 
 
4.3.3.4  Difficulty of refilling of medicine 
 
Out of the total number of respondents, 6.3% said that it was difficult for them to obtain 
refills on time, 2.3% said they did was hard, 10.3% said that it was sometimes difficult 
and sometimes easy, 80.8% said it was easy, and 0.5% said it was very easy for obtain 
their HIV medication refills on time. Of the respondents in this study, 81.3% of the 
population therefore felt that they were able to obtain the refills of their HIV medication 
on time. 
 
Table 4.23  Get your HIV medication refill on time 
 
Description Frequency Percent 
Very hard 25 6.3 
Hard 9 2.3 
Sometimes hard 34 8.5 
Sometimes easy 7 1.8 
Easy 323 80.8 
Very Easy 2 0.5 
Total 400 100.0 
 
 
4.3.3.5  Becoming too busy to take medication 
 
Out of the total number of respondents, 8.8% said it was very hard for them to take their 
HIV medication when they were wrapped up in what they were doing, 4.5% said that it 
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was hard, 26.1% said that it was sometimes hard and sometimes easy, 60.5% said it 
was easy for them to take their HIV medication even though they were wrapped up in 
what they were doing. This study shows that 60.5% of the respondents said they were 
able to take their HIV medication even when they were wrapped up in what they were 
doing. 
 
Table 4.24 Take HIV medication, during working time 
 
Description Frequency Percent 
Very hard 35 8.8 
Hard 18 4.5 
Sometimes hard 81 20.3 
Sometimes easy 23 5.8 
Easy 242 60.5 
Total respondents 399 99.8 
Missing 1 0.3 
Total 400 100.0 
 
 
4.3.3.6  Difficulty of managing medication side-effects  
 
Out of the total number of respondents, 5.3% said it was very hard for them to manage 
the side-effects of the HIV medication, 5% said that it was hard, 16.3% said that it was 
sometimes hard and sometimes easy, 72.3% said it was easy, and 1.3% said it was 
very easy to manage the side-effects of their HIV medication. The result of the survey 
showed that 73.6% of the respondents were of the opinion that they were able to 
manage the side-effects of their HIV medication. 
 
Table 4.25  Manage side-effects of HIV medication 
 
Description Frequency Percent 
Very hard 21 5.3 
Hard 20 5.0 
Sometimes hard 45 11.3 
Sometimes easy 20 5.0 
Easy 289 72.3 
Very Easy 5 1.3 
Total 400 100.0 
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4.3.3.7  Forgetfulness to take medication 
 
Out of the total number of respondents, 1.5% said it was very hard for them to 
remember to take their HIV medication, 2.3% said that it was hard for them to 
remember, 15.8% said that it was sometimes hard and sometimes easy for them to 
remember, 80.5% said it was easy for them to remember to take their prescribed HIV 
medication. These results indicate that 80.5% of the respondents were of the opinion 
that they were able to take their HIV medication on time. 
 
Table 4.26  Remember to take HIV medication 
 
Description Frequency Percent 
Very hard 6 1.5 
Hard 9 2.3 
Sometimes hard 46 11.5 
Sometimes easy 17 4.3 
Easy 322 80.5 
Total 400 100.0 
 
4.3.3.8 The pills are too inconvenient to swallow 
 
Out of the total number of respondents, 4% said it was very hard for them to take the 
medication, 3% said it was hard for them to take the medication, 16.5% said that it was 
sometimes hard and sometimes easy, and 76.3% said that it was easy for them to take 
their HIV medication despite the fact that the pills were hard to swallow, that they tasted 
bad and that they made one feel sick in one's stomach. These results show that 76.3% 
of the respondents felt that they could take their HIV medication even though the pills 
were hard to swallow, even though they tasted bad and even though they made them 
feel sick in their stomachs. 
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Table 4.27  HIV medication is hard to swallow because they taste bad or irritate 
stomach 
 
Description Frequency Percent 
Very hard 16 4.0 
Hard 12 3.0 
Sometimes hard 44 11.0 
Sometimes easy 23 5.8 
Easy 305 76.3 
Total 400 100.0 
 
 
4.3.3.9 Difficulty of making medication part of daily life 
 
Out of the total number of respondents, 1.3% said it was hard to incorporate the taking 
of HIV medication a regular part of daily life, 2.3% said it was hard, 10% said it was 
sometimes hard and sometimes easy, 85.8% said it was easy, and 8% said it was very 
easy to make HIV medication a regular part of their daily lives. The result show that 
93.8% of the respondents felt that they could incorporate the taking of HIV medication 
into the routine of their daily lives. 
 
Table 4.28  Make HIV medication part of daily life 
 
Description Frequency Percent 
Very hard 5 1.3 
Hard 9 2.3 
Sometimes hard 26 6.5 
Sometimes easy 14 3.5 
Easy 343 85.8 
Very easy 3 0.8 
Total 400 100.0 
 
4.3.3.10  A change in daily routine  
 
Out of the total number of respondents, 5.5% said that it was very hard to for them to 
stick to their treatment plan, 4.3% said it was hard, 15.8% said that it was sometimes 
hard and sometimes easy, 74% said it was easy, and 0.5% said it was very easy to 
stick to treatment plan when their daily routine changes. The study shows that 94% of 
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the respondents were committed to stick to the treatment plan even when their daily 
routine changes for example, when they travel or when they go out with their friends.  
 
Table 4.29  Take HIV medication when usual routine changes 
 
Description Frequency Percent 
Very hard 22 5.5 
Hard 17 4.3 
Sometimes hard 56 14.0 
Sometimes easy 7 1.8 
Easy 296 74.0 
Very easy 2 0.5 
Total 400 100.0 
 
 
4.3.3.11  Feel depressed or overwhelmed to take medication 
 
Out of the total number of respondents, 7.5% said it was very hard for them to take their 
HIV mediations when they were not feeling emotionally well, 4.3% said it was hard, 
24.8% said it was sometimes hard and sometimes easy, 63.3% said it was easy, and 
0.3% said that it was very easy. The results show that 63.6% of the respondents are 
able to take their HIV medication even when they are not feeling emotionally well. 
 
Table 4.30  Take HIV medication, when I don’t feel good emotionally 
 
Description Frequency Percent 
Very hard 30 7.5 
Hard 17 4.3 
Sometimes hard 72 18.0 
Sometimes easy 27 6.8 
Easy 253 63.3 
Very easy 1 0.3 
Total 400 100.0 
 
4.3.3.12  Felt well  
 
Out of the total number of respondents, 11.8% said it was very hard for them to take 
their HIV medication when they were feeling physically good and did not show any 
symptoms of their HIV disease, 3.8% said it was hard, 10.5% said it was sometimes 
hard and sometimes easy, 73.3% said it was easy, and 0.5% said it was very easy. The 
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results show that 73.8% of the respondents said that they were able to take their HIV 
medication even when they were feeling physically good and did not show any 
symptoms of their of their HIV disease. 
 
Table 4.31 Take HIV medication when I am good physically and don’t feel 
symptoms of HIV 
 
Description Frequency Percent 
Very hard 47 11.8 
Hard 15 3.8 
Sometimes hard 34 8.5 
Sometimes easy 8 2.0 
Easy 293 73.3 
Very Easy 2 0.5 
Total respondents 399 99.8 
Missing 1 0.3 
Total 400 100.0 
 
4.3.3.13 Felt sick 
 
Out of the total number of respondents, 5.8% said that it was very hard for them to take 
their HIV medication when they were not feeling physically well, 3.8% said that it was 
hard, 20.8% said that it was sometimes hard and sometimes easy, 68.8% said that it 
was easy, and 0.8% said it was very easy. The result shows that 69.6% of the 
respondents maintained that they were able to take their HIV medication even when 
they were not feeling physically good. 
 
Table 4.32  Take HIV medication, I don’t feel good physically 
 
Description Frequency Percent 
Very hard 23 5.8 
Hard 15 3.8 
Sometimes hard 66 16.5 
Sometimes easy 17 4.3 
Easy 275 68.8 
Very easy 3 0.8 
Total respondents 399 99.8 
Missing 1 0.3 
Total 400 100.0 
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4.3.3.14  Ability to talk to the HCP about the medication 
 
Out of the total number of respondents, 2.3% said it was very hard to talk to their health 
care providers about HIV medication and their side-effects and symptoms, 1.5% said it 
was hard, 10% said that it was sometimes hard and sometimes easy, 85.3% said it was 
easy, and 1% said that it was very easy. These results show that 86.3% of the 
respondents are unable to talk to their health care providers about HIV medication and 
their side-effects and symptoms. 
 
Table 4.33 Talk to health care provider about HIV medication 
 
Description Frequency Percent 
Very hard 9 2.3 
Hard 6 1.5 
Sometimes hard 28 7.0 
Sometimes easy 12 3.0 
Easy 341 85.3 
Very easy 4 1.0 
Total 400 100.0 
 
4.4 OVERVIEW OF RESEARCH FINDINGS  
 
4.4.1 Information status of patients 
 
The data were managed first by reversing and changing the five Likert Scale into two or 
dichotomised groups. Strongly disagree, disagree and neutral responses were grouped 
as having poor information and the rest of the responses, i.e., strongly agree and agree 
as good information. There is a total of nine items under information construct and 
responses such as strongly agree and agree were counted and summed for each 
respondent. The respondents with five and more than five strongly agree/agree out of 
the nine responses were decided as ‘good information’ and if four and below will be 
decided as having ‘poor information’. The median was used for deciding the cut-off point 
as good and poor information. 
 
Out of the total 400 respondents, 389 had good information and there were only eleven 
patients with poor information about adherence to ART. 
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Table 4.34a Information status of patients 
 
Information 
items 
Perceptions of patients 
Total Strongly 
disagree 
Somewhat 
disagree 
Neither 
agree nor 
disagree 
Somewhat 
agree 
Strongly 
agree 
Know HIV 
medication is 
supposed to 
be taken 
45 
(11.3) 
1 
(0.3) 
 
2 
(0.5) 
27 
(6.8) 
325 
(81.3) 
400 
(100.0) 
Know what to 
do if I miss a 
dose of 
medication 
241 
(60.3) 
14 
(3.5) 
5 
(1.3) 
52 
(13.0) 
88 
(22.0) 
400 
(100.0) 
Skipping few 
of my HIV 
medication 
will not really 
hurt my 
health 
18 
(4.5) 
8 
(0.5) 
2 
(2.0) 
5 
(1.3) 
367 
(91.8) 
400 
(100.0) 
Know the 
possible 
side-effect of 
my HIV 
medication 
 
59 
(14.8) 
14 
(1.0) 
4 
(3.5) 
79 
(19.8) 
243 
(60.8) 
399 
(99.8) 
As long as 
feeling health 
missing HIV 
medication is 
ok 
19 
(4.8) 
5 
(1.3) 
3 
(0.8) 
 
373 
(93.3) 
400 
(100.0) 
Understand 
HIV 
medication 
works to fight 
HIV 
20(5.0) 
 
 
7(1.8) 
 
 
3 (0.8) 
 
 
25 (6.3) 
 
 
 
344 
(86.0) 
 
 
399 (99.8) 
 
If don’t take 
my HIV 
medication, 
may not work 
for the future 
196 
(49.0) 
18 
(4.5) 
5 
(1.3) 
80 
(20.0) 
100 
(25.0) 
399 
(99.8) 
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Information 
items 
Perceptions of patients 
Total Strongly 
disagree 
Somewhat 
disagree 
Neither 
agree nor 
disagree 
Somewhat 
agree 
Strongly 
agree 
If take my HIV 
medication, 
live longer 
6 
(1.5) 
2 
(0.5) 
3 
(0.8) 
12 
(3.0) 
375 
(93.8) 
398 
(99.5) 
Know HIV 
medication 
interact with 
Alcohol and 
other 
substances 
48 
(12.0) 
4 
(1.0) 
5 
(1.3) 
30 
(7.5) 
312 
(78.0) 
399 
(99.8) 
 
Table 4.34b Information status of patients 
 
Information status of 
patients 
Frequency Percent Valid percent Cumulative percent 
Valid 
Poor in information 11 2.8 2.8 2.8 
Good in information 389 97.3 97.3 100.0 
Total 400 100.0 100.0  
 
 
 
 
Figure 4.1 Information status of patients 
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4.4.2  Motivation of patients towards ART adherence 
 
With the same data management, whether the patients have good motivation or not 
were decided by taking the median as a cut-off point. Those respondents with six and 
above out of ten were decided to have good motivation and those with five and below 
were decided to have poor motivation.  
 
Out of the total 400 respondents, 351 had good motivation and there were 49 patients 
with poor motivation to adhere to ART medication. 
 
Table 4.35a  Motivation status of patients 
 
Motivation items 
Perceptions of patients 
Total 
Strongly 
disagree 
Somewhat 
disagree 
Neither 
agree 
nor 
disagree 
Somewhat 
agree 
Strongly 
agree 
Worried HIV+, if 
people see me 
taking my HIV 
medication 
75 
(18.8) 
78 
(19.5) 
3 
(0.8) 
16 
(4.0) 
227 
(56.8) 
399 
(99.8) 
Frustrated taking 
HIV medication 
around my life 
54 
(13.5) 
52 
(13.0) 
2 
(0.5) 
10 
(2.5) 
282 
(70.5) 
400 
(100.0) 
Don’t like taking 
my HIV medication, 
reminds me that I 
am HIV+ 
34 
(8.5) 
9 
(2.3) 
 
2 
(0.5) 
355 
(88.8) 
400 
(100.0) 
Feel that health 
care provider 
recommendations 
31 
(7.8) 
19 
(4.8) 
2 
(0.5) 
86 
(21.5) 
260 
(65.0) 
398 
(99.5) 
People are 
important for 
taking HIV 
medication 
41 
(10.3) 
5 
(1.3) 
2 
(0.5) 
50 
(12.5) 
301 
(75.3) 
399 
(99.8) 
Health care 
provider doesn’t 
give enough 
30 
(7.5) 
24 
(6.0) 
2 
(0.5) 
11 
(2.8) 
333 
(83.3) 
400 
(100.0) 
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Motivation items 
Perceptions of patients 
Total 
Strongly 
disagree 
Somewhat 
disagree 
Neither 
agree 
nor 
disagree 
Somewhat 
agree 
Strongly 
agree 
support 
Frustrate to take 
HIV medication for 
life long 
38 
(9.5) 
27 
(6.8) 
2 
(0.5) 
15 
(3.8) 
318 
(79.5) 
400 
(100.0) 
Worried HIV 
medication hurt my 
health 
31 
(7.8) 
41 
(10.3) 
2 
(0.5) 
12 
(3.0) 
314 
(78.5) 
400 
(100.0) 
Upsets HIV 
medication, Affect 
the way I look 
44 
(11.0) 
86 
(21.5) 
7 
(1.8) 
7 
(1.8) 
256 
(64.0) 
400 
(100.0) 
I am up upset by 
HIV medication, 
they cause side-
effects 
49 
(12.3) 
82 
(20.5) 
3 
(0.8) 
16 
(4.0) 
249 
(62.3) 
399 
(99.8) 
 
Table 4.35b  Motivation status of patients towards ART 
 
Motivation of patients 
towards ART 
Frequency Percent Valid percent Cumulative percent 
Valid 
Poor motivation 49 12.3 12.3 12.3 
Good motivation 351 87.8 87.8 100.0 
Total 400 100.0 100.0  
 
 
Figure 4.2  Motivation of patients towards ART 
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4.4.3  Behavioural skills of patients relevant to ART adherence 
 
Out of the total of 14 behavioural skills items in the study questionnaire, if a 
respondent scored 8 and above easy/very easy responses they will be decided as 
having good behavioural skills and those with 7 and below easy/very easy responses 
were decided as having poor or inadequate behavioural skills important to adhere to 
ART. 
 
Out of the total of 400 respondents, 328 had adequate behavioural skills and 72 had 
inadequate behavioural skills. 
 
Table 4.36a Behavioural skills status of patients relevant for ART adherence 
 
Behavioural 
skill items 
Perceptions of patients  
Total 
Strongly 
disagree 
Somewhat 
disagree 
Neither 
agree nor 
disagree 
Somewhat 
agree 
Strongly 
agree 
 
It is hard 
taking HIV 
medication, 
while 
drinking 
alcohol or 
using drugs 
157 
32 
5 
4 
202 
400 
39.3 
8.0 
1.3 
1.0 
50.5 
100.0 
     
Behavioural 
skill items 
continued 
Very hard Hard 
Sometimes 
hard 
Sometimes 
easy 
Easy 
Very 
easy 
Total 
Informing 
about HIV 
treatment 
15 
(3.8) 
12 
(3.0) 
28 
(7.0) 
21 
(5.3) 
321 
(80.3) 
3 
(0.8) 
400 
(100.0) 
Get support 
from others 
for taking HIV 
medication 
14 
(3.5) 
4 
(8.8) 
35 
(1.0) 
14 
(3.5) 
327 
(81.8) 
6 
(1.5) 
 
400 
(100.0) 
Get your HIV 
medication 
refill on time 
25 
(6.3) 
9 
(2.3) 
34 
(8.5) 
7 
(1.8) 
323 
(80.8) 
2 
(0.5) 
400 
(100.0) 
Take HIV 
medication, 
during 
working time 
35 
(8.8) 
18 
(20.3) 
81 
(4.5) 
23 
(5.8) 
242 
(60.5) 
 
399 
(99.8) 
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Behavioural 
skill items 
Perceptions of patients  
Total 
Strongly 
disagree 
Somewhat 
disagree 
Neither 
agree nor 
disagree 
Somewhat 
agree 
Strongly 
agree 
 
Manage side-
effect of HIV 
medication 
21 
(5.3) 
20 
(5.0) 
45 
(11.3) 
20 
(5.0) 
289 
(72.3) 
5 (1.3) 400 
(100.0) 
Remember to 
take HIV 
medication 
6 
(1.5) 
9 
(2.3) 
46 
(11.5) 
 
17 
(4.3) 
322 
(80.5) 
 400 
(100.0) 
HIV 
medication 
hard to 
swallow taste 
bad or sick 
stomach 
16 
(4.0) 
12 
(3.0) 
44 
(11.0) 
23 
(5.8) 
305 
(76.3) 
 400 
(100.0) 
Make HIV 
medication 
part of daily 
life 
5 
(1.3) 
9 
(2.3) 
26 
(6.5) 
14 
(3.5) 
343 
(85.8) 
3 
(0.8) 
400 
(100.0) 
Take HIV 
medication. 
usual routine 
changes 
22 
5.5) 
17 
(4.3) 
56 
(14.0) 
7 
(1.8) 
296 
(74.0) 
2 
(0.5) 
400 
(100.0) 
Take HIV 
medication. 
don’t feel 
good 
emotional 
30 
(7.5) 
17 
(4.3) 
72 
(18.0) 
27 
(6.8) 
253 
(63.3) 
1 
(0.3) 
400 
(100.0) 
Take HIV 
medication 
when good 
physically 
and don’t feel 
symptoms of 
HIV take HIV 
medication. 
don’t feel 
good 
physically 
47 
(11.8) 
15 
(3.8) 
34 
(8.5) 
8 
(2.0) 
293 
(73.3) 
2 
(0.5) 
399 
(99.8) 
Talk to health 
care provider 
about HIV 
medication 
23 
(5.8) 
15 
(3.8) 
66 
(16.5) 
17 
(4.3) 
275 
(68.8) 
3 
(0.8) 
399 
(99.8) 
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Table 4.36b  Behavioural skills status of patients relevant for ART adherence 
 
 
Behavioural skill status of 
patients 
Frequency Percent Valid percent Cumulative percent 
Poor behavioural skill 72 18.0 18.0 18.0 
Good behavioural skill 328 82.0 82.0 100.0 
Total 400 100.0 100.0  
 
 
 
Figure 4.3  Behavioural skill status of patients 
 
4.4.4  Patients reported rates of adherence 
 
Respondents were asked how many doses they had missed in the previous three days. 
Their replies were used to calculate the percentage of those who took <95% or >95% of 
the ARV medication prescribed. Table4.37 shows the results of the question about how 
many doses each patient had missed during the previous three days. 
 
Table 4.37  The percentage of ARV doses taken by the respondents in the three 
days preceding the study (N=400) 
 
Description Frequency Percent 
Not adhere 37 9.3 
Adhere 363 90.8 
Total 400 100.0 
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Complete adherence data were provided by 400 participants. Three hundred and sixty-
three participants (90.75%) reported optimal adherence (95% or greater rates of 
adherence) and 37 participants (9.25%) reported sub-optimal adherence (less than 95% 
rates of adherence). This dichotomous variable, with optimal adherence scored as one 
and sub-optimal adherence scored as zero, served as the outcome variable in the 
analyses. This study found a better adherence level than previously reported from 
Ethiopia (Awel 2007:40; Tadios & Davey 2006:41) except studies by Amberbir et al 
(2008:7) and Zeleke and Thupayagale-Tshweneagae (2013). 
 
 
 
Figure 4.4  Self-reported adherence score among respondents 
 
4.4.5 Overview of research findings from inferential statistics 
 
The IMB model of ART adherence was assessed as free and restricted models using 
variables from the three constructs and the dichotomous dependent variable: 
adherence-related information, motivation, and behavioural skills are the covariates 
while adherence per se (defined as optimal versus sub-optimal adherence) is the 
outcome or dependent variable.  In the first free model, each variable from each 
construct was tested for adherence without adjusting values; the variables were then 
tested collectively for adherence behaviour. The p-values shown on the free models are 
the overall p-value for each path as a construct. From the analysis, it was found that 
motivation and adherence behavioural skills were significantly associated with 
adherence while information was not significantly associated with adherence.  
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Further, in the second free model, information was tested univariately first with 
motivation and then with adherence behavioural skills; motivation was also tested 
univariately with adherence behavioural skills. The results show that although 
information was not directly associated with motivation or behavioural skills, motivation 
was found to be directly and strongly associated with behavioural skills with a p-value of 
0.00. This shows an association between motivation and behavioural skills in the 
second free model analysis and an association between motivation and adherence 
behaviour in the first free model analysis.  
 
In the restricted model, every variable from each construct was screened with a p-value 
of 0.25 and later tested with adjusted odds ratio with a p-value of 0.05. One variable, 
i.e., the first variable from the information construct was found to be significantly but 
negatively associated with adherence behaviour while four variables from behavioural 
skills were significantly and positively associated with adherence behaviour. There were 
no significant associations between motivation variables and adherence behaviour. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 Free Model 1 
  
Adherence 
information 
Adherence 
behavioural skills 
Adherence 
motivation 
ART adherence 
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P-value 0.000 
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Figure 4.6 A Restricted Model 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7 Free Model 2 
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information 
Adherence 
behavioural skills 
Adherence 
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P-value 0.108 
P-value 
0.543 
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4.4.5.1 The impact of information on ART adherence behaviour 
 
From 2x2 chi square analysis between information and adherence to medication, no 
significant association was found between the information variables and adherence 
behaviour when the information variables were tested individually as well as collectively. 
The tables show that the p-values are greater than 0.05 in both cases.  
 
Table 4.38a  Assessment of the direct association between information and 
adherence behaviour 
 
Information items 
Adherence to 
medication Chi-
square 
value 
P-
value 
Not 
adherent 
Adherent 
Know HIV medication is supposed to 
be taken 
Not well-informed 2 
(0.5%) 
46 
(11.5%) 
1.679 0.195 
Well-informed 35 
(8.8%) 
317 
(79.2%) 
Know what to do if I miss a dose of 
medication 
Not well-informed 26 
(6.5%) 
234 
(58.5%) 
0.498 0.48 
Well-informed 11 
(2.8%) 
129 
(32.2%) 
Skipping few of my HIV medication will 
not really hurt my health 
Not well-informed 32 
(8%) 
340 
(85%) 
2.657 0.103 
Well-informed 5 
(1.2%) 
23 
(5.8%) 
Know the possible side-effect of my 
HIV medication 
Not well-informed 10 
(2.5%) 
67 
(16.8%) 
1.586 0.271 
Well-informed 27 
(6.8) 
296 
(74%) 
As long as feeling health missing HIV 
medication is ok 
Not well-informed 33 
(8.2%) 
343 
(85.8) 
1.673 0.262 
Well-informed 4 
(1%) 
20 
(5%) 
Understand HIV medication works to 
fight HIV 
Not well-informed 2 
(0.5%) 
28 
(7%) 
0.258 1.000 
Well-informed 
35(8.8%) 
335 
(83.8) 
If don’t take my HIV medication, it may 
not work for the future 
Not well-informed 18 
(4.5%) 
20 
(50.2%) 
0.613 0.490 
Well-informed 19 
(4.8%) 
162 
(40.5%) 
If I take my HIV medication, I live 
longer 
Not well-informed 1 
(0.2%) 
10 
2.5%) 
0.000 1.000 
Well-informed 36 
(9%) 
353 
(88.2%) 
Know HIV medication interact with 
alcohol and street drugs 
Not well-informed 8 
(2%) 
49 
(12.2%) 
1.813 0.213 
Well-informed 29 
(7.2%) 
314 
(78.5%) 
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Table 4.38b  Assessment of the direct association between information and 
adherence behaviour 
 
Information 
status of 
patients 
Adherence to medication 
Chi-square 
value 
P-value 
Not adherent Adherent 
Poor information 2 
(0.5%) 
9 
(2.2%) 
1.075 0.270 
Good information 35 
(8.8%) 
354 
(88.5%) 
 
 
4.4.5.2 The impact of motivation on ART adherence behaviour 
 
From 2x2 chi square analysis between motivation and adherence to medication, with 
the exception of item 6 there is significant association between the motivation variables 
and adherence behaviour when the motivation variables were tested individually as well 
as collectively. The tables show that the p-values are less than 0.05 in both cases.  
 
 
Table 4.39a Assessment of the direct association between motivation and ART 
adherence behaviour 
 
 
Motivation items 
Adherence to 
medication 
Chi-
square 
value 
P-
value Not 
adherent 
Adherent 
Worried HIV+, if people see me taking 
my HIV medication 
Not  
well-motivated 
13 
(3.2%) 
234 
(58.5%) 
12.227 0.000 
Well-motivated 
24 
(6%) 
129 
(32.2%) 
Frustrated taking HIV medication 
around my life 
Not  
well-motivated 
22 
(5.5%) 
272 
(68.0%) 
4.127 0.051 
Well-motivated 
15 
(3.8%) 
91 
(22.8%) 
Don’t like taking HIV my HIV 
medication, HIV+ 
Not  
well-motivated 
27 
(6.8%) 
330 
(82.5%) 
11.259 0.003 
Well-motivated 
10 
(2.5%) 
33 
(8.2%) 
Feel that health care provider 
recommendations 
Not  
well-motivated 
11 
(2.8%) 
41 
(10.2%) 
10.090 0.004 
Well-motivated 
26 
(6.5%) 
322 
(80.5%) 
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Motivation items 
Adherence to 
medication 
Chi-
square 
value 
P-
value Not 
adherent 
Adherent 
People are important for taking HIV 
medication 
Not  
well-motivated 
9 
(2.2%) 
39 
(9.8%) 
5.864 0.029 
Well-motivated 
28 
(7.0%) 
324(81.0%) 
Health care provider doesn’t give 
enough support 
Not  
well-motivated 
34 
(8.5%) 
312 
(78.0%) 
1.015 0.449 
Well-motivated 
3 
(0.8%) 
51 
(12.8%) 
Frustrate to take HIV medication for life 
long 
Not  
well-motivated 
21 
(5.2%) 
314 
(78.5%) 
21.829 0.000 
Well-motivated 
16 
(4.0%) 
49 
(12.2%) 
Worried HIV medication, hurt my health 
Not  
well-motivated 
21 
(5.2%) 
307 
(76.8%) 
17.602 0.000 
Well-motivated 
16 
(4.0%) 
56 
(14.0%) 
Upsets HIV medication, affect the way I 
took 
Not  
well-motivated 
15 
(3.8%) 
255 
(63.8%) 
13.508 0.001 
Well-motivated 
22 
(5.5%) 
108 
(27.0%) 
Upsets HIV medication , cause side-
effects 
Not  
well-motivated 
18 
(4.5%) 
251 
(62.8%) 
6.405 0.016 
Well-motivated 
19 
(4.8%) 
112 
(28.0%) 
 
Table 4.39b Assessment of the direct association between motivation and ART 
adherence behaviour 
 
Information 
status of 
patients 
towards ART 
Adherence to medication 
Chi-square 
value 
P-value 
Not adherent Adherent 
Poor information 
13 
(3.2%) 
36 
(9.0%) 
19.865 0.000 
Good information 
24 
(6.0%) 
327 
(81.8%) 
 
4.4.5.3 The impact of behavioural skills on ART adherence behaviour 
 
From 2x2 chi square analysis between motivation and adherence to medication, with 
the exception of the first item there is significant association between the behavioural 
skills variables and adherence behaviour when the behavioural skills variables were 
tested individually as well as collectively. The tables show that the p-values are less 
than 0.05 in both cases.  
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Table 4: 40a Assessment of the association between behavioural skills and 
adherence behaviour 
 
Behavioural skills items 
Adherence to 
medication 
Chi-
square 
value 
P-
value 
Not 
adherent 
Adherent 
Hard taking HIV medication, drinking 
alcohol or use street drugs 
Inadequate skill 22 
(5.5%) 
189 
(47.2%) 
0.736 0.391 
Adequate skill 15 
(3.8%) 
174 
(43.5%) 
Informing about HIV treatment 
Inadequate skill 18 
(4.5%) 
58 
(14.5%) 
23.288 0.000 
Adequate skill 19 
(4.8%) 
305( 
46.2%) 
Get support from others for taking HIV 
medication 
Inadequate skill 18 
(4.5%) 
49 
(12.2%) 
29.751 0.000 
Adequate skill 19 
(4.8%) 
314 
(78.5%) 
Get your HIV medication refill on time 
Inadequate skill 22 
(5.5%) 
53 
(13.2%) 
44.353 0.000 
Adequate skill 15 
(3.8%) 
310 
(77.5%) 
Wrap HIV medication, during working 
time 
Inadequate skill 27 
(6.8%) 
130 
(32.5%) 
19.446 0.000 
Adequate skill 10 
(2.5%) 
233 
(58.2%) 
Manage side-effect of HIV medication 
Inadequate skill 26 
(6.5%) 
80 
(20.0%) 
40.103 0.000 
Adequate skill 11 
(2.8%) 
283 
(70.8%) 
Remember to take HIV medication 
Inadequate skill 20 
(5.0%) 
58 
(14.5%) 
31.011 0.000 
Adequate skill 17 
(4.2%) 
305 
(76.2%) 
HIV medication hard to swallow taste 
bad or sick stomach 
Inadequate skill 22 
(5.5%) 
73 
(18.2%) 
28.709 0.000 
Adequate skill 15 
(3.8%) 
290 
(72.5%) 
Make HIV medication part of daily life 
Inadequate skill 16 
(4.0%) 
38 
(9.5%) 
30.887 0.000 
Adequate skill 21 
(5.2%) 
32 
5(81.2%) 
Take HIV medication. usual routine 
changes 
Inadequate skill 25 
(6.2%) 
77 
(19.2%) 
37.980 0.000 
Adequate skill 12 
(3.0%) 
286 
(71.5%) 
Take HIV medication. don’t feel good 
emotional 
Inadequate skill 32 
(8.0%) 
114 
(28.5%) 
43.954 0.000 
Adequate skill 5 
(1.2%) 
249 
(62.2%) 
Take HIV medication, good physically Inadequate skill 25 79 36.615 0.000 
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Behavioural skills items 
Adherence to 
medication 
Chi-
square 
value 
P-
value 
Not 
adherent 
Adherent 
and don’t feel symptoms of HIV (6.2%) (19.8%) 
Adequate skill 12 
(3.0%) 
284 
(71.0%) 
Take HIV medication. don’t feel good 
physically 
Inadequate skill 27 
(6.8%) 
94 
(23.5%) 
35.270 0.000 
Adequate skill 10 
(2.5%) 
269 
(67.2%) 
Talk to health care provider about HIV 
medication 
Inadequate skill 13 
(3.2%) 
42 
(10.5%) 
15.722 0.000 
Adequate skill 24 
(6.0%) 
321 
(80.2%) 
 
Table 4:40b Assessment of the association between behavioural skills and 
adherence behaviour 
 
Behavioural 
skill status of 
patients 
Adherence to medication 
Chi-square 
value 
P-value Not adherent Adherent 
Poor skill 
27 
(6.8%) 
45 
(11.2%) 
83.477 0.000 
Good skill 
10 
(2.5%) 
318 
(79.5%) 
 
4.4.5.4 The impact of the integration of information, motivation and behavioural 
skills which were found to be associated with adherence behaviour 
 
From the adjusted value, from information variables “Know HIV medication is supposed 
to be taken” is statistically significant and the odds ratio is greater than one. Therefore, 
well-informed patients are more likely to have adherent than those of non-informed 
patients. The other results can be interpreted similarly. The other variables found to be 
associated are the following and they are positively associated: 
 
Get your HIV Medication refill on time 
Manage side-effect of HIV Medication 
Take HIV Medication. Don’t feel good emotionally 
Take HIV Medication. Good physically and don’t feel symptoms of HIV 
 
  
 
Table 4.41 Assessment of the association between information and motivation with behavioural skills assumed to bring the 
required adherence behaviour (the Bivariate and multivariate analysis results of adherence) 
 
Independent 
variables  
Information variables COR (95%) 
P-value 
COR 
AOR (95%) 
P-value 
AOR 
 
Information Know HIV medication is supposed to be taken 
Well-informed 
2.39 (0.591, 10.914) 
0.210 
8.391 (1.04, 71.54) 
0.049 
Not well-informed 
1 1 
Know what to do if I miss a dose of medication 
Well-informed 
1.3  (0.624, 2.72) 
0.481 
2.784 (0.25, 8.17) 
0.902 
Not well-informed 
1 1 
Skipping few of my HIV medication will not really 
hurt my health 
Well-informed 
0.532 (0.173, 1.637) 
0.271 
1.469 (1,02, 4.95) 
0.513 
Not well-informed 
1 1 
Know the possible side-effect of my HIV medication 
Well-informed 
1.64 (0.756, 3.54) 
0.212 
1.34 (0.423, 4.23) 
0.621 
Not well-informed 
1 1 
As long as feeling health missing HIV medication is 
ok 
Well-informed 
0.481 (0.155, 1.491) 
0.205 
0.797 (0.121, 5.262) 
0.579 
Not well-informed 
1 1 
Understand HIV medication works to fight HIV 
Well-informed 
0.684 (0.156, 2.992) 
0.614 
2.96 (1.02, 7.88) 
0.774 
Not well-informed 
1 1 
If don’t take my HIV medication, it may not work for 
the future 
Well-informed 
1.31 (0.665, 2.58) 
0.435 
3.55 (1.27, 7.99) 
0.758 
Not well-informed 
1 1 
If I take my HIV medication, I live longer 
Well-informed 
1.02 (0.127, 8.2) 
0.985 
2.5 (0.66, 7.9) 
0.66 
Not well-informed 
1 1 
8
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Independent 
variables  
Information variables COR (95%) 
P-value 
COR 
AOR (95%) 
P-value 
AOR 
Know HIV medication interact with alcohol and 
street drugs 
Well-informed 
0.566 (0.245, 1.31) 
0.183 
1.48 (0.369, 5.95) 
0.579 
Not well-informed 
1 1 
Motivation  
Worried HIV+, if people see me taking my HIV 
medication 
Well-motivated 
3.35 (1.45, 6.8) 
0.001 
2.3 (0.79, 6.8) 
0.126 
Not well-motivated 
1 1 
Frustrated taking HIV medication around my life 
Well-motivated 
2.34 (1.01, 4.095) 
0.046 
1.32 (0.46, 3.75) 
0.61 
Not well-motivated 
1 1 
Don’t like taking HIV my HIV medication, HIV+ 
Well-motivated 
3.704 (1.65, 8.32) 
0.002 
2.97 (0.88, 10.10) 
0.08 
Not well-motivated 
1 1 
Feel that health care provider recommendations 
Well-motivated 
0.301 (0.138, 0.654) 
0.002 
0.344 (0.102, 0.17) 
0.087 
Not well-motivated 
1 1 
People are important for taking HIV medication 
Well-motivated 
0.374 (0.165, 0.851) 
0.019 
0.74 (0.21, 0.27) 
0.67 
Not well-motivated 
1 1 
Health care provider doesn’t give enough support 
Well-motivated 
0.54 (0.16, 1.823) 
0.321 
2.4 (1.55, 8.93) 
0.33 
Not well-motivated 
1 1 
Frustrate to take HIV medication for life long 
Well-motivated 
4.882 (2.39, 9.99) 
0.000 
1.5 (0.48,4.7) 
0.489 
Not well-motivated 
1 1 
Worried HIV medication, hurt my health 
Well-motivated 
4.18 (2.053, 8.496) 
0.000 
1.1 (0.323.8) 
0.891 
Not well-motivated 
1 1 
Upsets HIV medication, affect the way I took Well-motivated 
3.46 (1.73, 6.93) 0.000 1.4 (0.42, 4.43) 0.612 
8
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Independent 
variables  
Information variables COR (95%) 
P-value 
COR 
AOR (95%) 
P-value 
AOR 
Not well-motivated 
1 1 
Upsets HIV medication, cause side-effects 
Well-motivated 
2.37 (1.196, 4.68) 
0.013 
0.88 (0.28, 2.75) 
0.831 
Not well-motivated 
1 1 
Behavioural 
skill 
Hard taking HIV medication, drinking alcohol or use 
street drugs 
Adequate skill 
0.741 (0.372, 1.47) 
0.392 
1.42 (0.19, 7.55) 
0.564 
Inadequate skill 
1 1 
Informing about HIV treatment 
Adequate skill 
0.201 (0.099, 0.405) 
0.000 
1.1 (0.36, 3.3) 
0.886 
Inadequate skill 
1 1 
Get support from others for taking  HIV medication 
Adequate skill 
0.165(0.081, 0.336) 
0.000 
0.63 (0.1.94, 2.03) 
0.436 
Inadequate skill 
1 1 
Get your HIV medication refill on time 
Adequate skill 
1.117 (0.057, 3.239) 
0.000 
0.304 (0.104, 0.89) 
0.030 
Inadequate skill 1 1 
Wrap HIV medication, during working time 
Adequate skill 
0.207 (0.097, 0.440) 
0.000 
1.2 (0.39, 3.6) 
0.78 
Inadequate skill 
1 1 
Manage side-effect of HIV medication 
Adequate skill 
1.12 (0.057, 2.253) 
0.000 
0.254 (0.083, 0.776) 
0.016 
Inadequate skill 
1 1 
Remember to take HIV medication 
Adequate skill 
0.162 (0.08, 0.327) 
0.000 
1.5 (0.41, 5.51) 
0.544 
Inadequate skill 
1 1 
HIV medication hard to swallow taste bad or sick 
stomach 
Adequate skill 
0.172 (0.085, 0.347) 
0.000 
0.82 (0.29, 2.29) 
0.706 
Inadequate skill 
1 1 
8
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Independent 
variables  
Information variables COR (95%) 
P-value 
COR 
AOR (95%) 
P-value 
AOR 
Make HIV medication part of daily life 
Adequate skill 
0.153 (0.074, 0.319) 
0.000 
1.63 (0.43, 6.20) 
0.472 
Inadequate skill 
1 1 
Take HIV medication. usual routine changes 
Adequate skill 
0.129 (0.062, 0.269) 
0.000 
0.98 (0.284, 3.39) 
0.975 
Inadequate skill 
1 1 
Take HIV medication - don’t feel good emotional 
Adequate skill 
2.072 (0.027, 6.188) 
0.000 
0.15 (0.043, 0.521) 
0.003 
Inadequate skill 
1 1 
Take HIV medication. good physically and don’t feel 
symptoms of HIV 
Adequate skill 
1.134 (0.064, 2.178) 
0.000 
0.24 (0.083, 0.704) 
0.009 
Inadequate skill 
1 1 
Take HIV medication. don’t feel good physically 
Adequate skill 
0.129 (0.06, 0.277) 
0.000 
0.383 (0.13, 1.14) 
0.084 
Inadequate skill 
1 1 
Talk to health care provider about HIV medication 
Adequate skill 
0.242 (0.114, 0.510) 
0.000 
1.2 (0.35, 3.37) 
0.889 
Inadequate skill 
1 1 
 
 
8
8
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4.5 CONCLUSION 
 
The main content included in this chapter are: Information factors, motivation factors, 
behavioural skills, patient reported rate of adherence, overview of research findings, 
and finally, a conclusion with respect to the chapter.  
 
This chapter discussed the results and interpretation of data analysis with reference to 
the literature review. The results were presented in the form of tables and figures.  
 
Chapter 5 concludes the study by drawing conclusions, discussing limitations and 
making certain recommendations for further research and practice in this field.  
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CHAPTER 5 
 
CONCLUSIONS AND RECOMMENDATIONS 
 
 
5.1 INTRODUCTION 
 
The purpose of this study was to assess the level of adherence to ART at the Felege 
Hiwot hospital among adult HIV-infected patients and to identify the major factors that 
affect adherence to ART. It is expected that the result of the study will be used to 
address the challenges that patients experience and to encourage them to adhere 
strictly to ART so that it can be optimally efficacious.  
 
Although strict adherence to the dosage regimen of ARV drugs is critical for the success 
of ART, no study has been done at the Felege Hiwot hospital to identify and assess the 
factors that affect the level of patient adherence to the ART dosage regimen. Since the 
long term success of ART is totally dependent on strict long-term adherence to the 
dosage schedules, the researcher used theoretical constructs derived from the IMB 
model, which worked well in the developed countries, to identify and assess factors 
affecting drug adherence among HIV-positive patients. By using the predictors 
associated with the IMB model, the researcher was able in this study to identify those 
factors that affect adherence.  
 
In this chapter, the researcher makes various recommendations for practice and further 
research in the field and identifies the limitations of the study. The chapter also 
presented conclusions based on results of a study to answer objectives formulated in 
Chapter 1 as follows:  
 
 To assess the levels of ART adherence behaviour in patients taking ARV drugs 
at Felege Hiwot hospital which located in Bahir Dar town of the Amhara region of 
Ethiopia. 
 To explore the impact of information about ART and adherence on ART 
adherence behaviour among patients receiving ARV drugs from Felege Hiwot 
hospital. 
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 To explore the impact of motivation on ART adherence behaviour among 
patients receiving ARV drugs from Felege Hiwot hospital. 
 To determine the impact of adherence behavioural skills needed to practice strict 
ART adherence on their self-reported adherence behaviour of patients at Felege 
hiwot hospital ART clinic. 
 To assess the benefits of the integration of information, motivation and 
behavioural skills needed to practise strict ART adherence in patients receiving 
ARV drugs from Felege Hiwot hospital. 
 
5.2 SUMMARY AND INTERPRETATION OF THE RESEARCH FINDINGS 
 
The findings from this study are discussed below in the same sequence in which the 
objectives of the study were listed above. 
 
Objective 1: To assess the level of adherence behaviour among ART patients who 
receive ARV drugs at the Felege Hiwot hospital. 
 
5.2.1 Level of adherence behaviour 
 
Out of the total number of respondents, 9.25% respondents took their HIV medications 
<95% of the time, while 90.75% of the respondents took their ART medications for 
>95% within the 3 days preceding the study.  
 
Although this represents a good adherence rate, it still indicates that a significant 
number of the population is sub-optimally adherent to ART. This poses a serious threat 
because when ARV medications are taken intermittently, they develop an increasing 
inability to combat the HIV virus therefore, negates the efficacy of the ART regimen in 
the future. This obviously poses an enormous threat to the overall health status of 
individuals and of the community as a whole because the selection of ARV drugs that 
are available to patients in developing countries such as Ethiopia, are very limited 
indeed. Health care professionals who administer ARV therefore need to take urgent 
action in order to improve the level of optimal adherence among those who are currently 
receiving ARV medications.  
 
The researcher measured ART adherence by self-report using structured interview 
questions that can be subject to overestimation, as patients tend to overstate their 
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adherence to treatment. Other measures of adherence, such as pill counts, pharmacy 
records, electronic devices, or therapeutic drug monitoring were not available for the 
study. Even so, measuring adherence using patients’ self-report can be easily replicated 
in most resource-limited settings including Ethiopia making it a good measure for 
comparison (Amberbir et al 2008:5-7; Reda & Biadgilign 2012:2).  
 
Objective 2: To explore the impact of information about ART and adherence on ART 
adherence behaviour among patients receiving ARV drugs from Felege Hiwot hospital. 
 
5.2.2 The impact of information on ART adherence behaviour 
  
The study was able to show that information is an important determinant factor for 
adherence behaviour. Non-adherence is understood in terms of characteristics of the 
patient (personality traits, socio-demographic background), and patient factors are seen 
as the targets of efforts to improve adherence. This approach has helped to elucidate 
the relationships between disease and treatment characteristics on the one hand, and 
adherence on the other. Technological innovations (e.g. assessing levels of adherence 
using biochemical measures, developing new devices to administer medications) have 
had this as their impetus. Other important factors, such as patients’ views about their 
symptoms or their medications have been largely ignored. Behavioural (learning) theory 
emphasises the importance of positive and negative reinforcement as a mechanism for 
influencing behaviour, and this has immediate relevance for adherence. 
 
Clinicians need to communicate information effectively to patients. They need to: 
 
 Build trust and encourage patients to participate in decision-making and to be 
partners in their own health care. 
 Ask patients to share why and how they will carry out their treatment 
recommendations. Listen to patients' concerns and give them full attention. 
 Be aware of and sensitive to patient's cultural beliefs and practices, and view 
treatment through a cultural lens to make sure that recommendations do not 
conflict with cultural norms. 
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Objective 3: To explore the impact of motivation on ART adherence behaviour among 
patients receiving ARV drugs from Felege Hiwot hospital. 
 
5.2.3 The impact of motivation on ART adherence behaviour 
 
The study analysis has shown that motivation and adherence behaviour are significantly 
and strongly associated. Negative attitudes toward treatment and demotivation to follow 
treatment recommendations come from lack of optimal knowledge about the efficacy of 
the treatment. Motivation, beliefs and actions come from knowledge, therefore, 
delivering specific information pertaining to the desired behavioural outcome is the basic 
tool which brings about the knowledge about a medical condition that might include how 
the disease develops, its expected course and effective strategies for its management. 
Therefore, teaching patients until they are fully aware of the benefits of strictly adhering 
to treatment is very important because patients become motivated to follow only 
treatments they are convinced of.  This means that even if the patient has acquired 
knowledge from the information given and gets training on relevant skills, he or she may 
not use the knowledge and skill until he or she has the conviction and belief on the 
knowledge processed from the given information, which means they should be 
convinced of the subject matter in order to move to action or targeted practice. 
 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 5.1   The information-motivation cascade diagramme 
(Source: self-created) 
 
Information Knowledge Belief Attitude Motivation 
Practice 
Skill 
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Objective 4: To determine the impact of adherence behavioural skills needed to 
practice strict ART adherence. 
 
5.2.4 The impact of behavioural skills on ART adherence behaviour 
 
Patients need behavioural skills which ensure that the patient has the specific 
behavioural tools or strategies necessary to perform the adherence behaviour such as 
enlisting social support and other self-regulation strategies, to achieve this, HCPs need 
to improve their skills in communicating with their patients which is very important to 
guide and help their patients to create not only knowledge and motivation but also 
behavioural skills.  
 
This leads to emphasis being placed on the importance of developing rapport, 
educating patients, employing good communication skills and stressing the desirability 
of a more equal relationship between patient and health professional. With regard to 
communication interventions per se, recent developments have foregrounded the need 
to move beyond top-down communication towards horizontal and participatory 
approaches. Such approaches incorporate the concept of addressing enabling 
environments and contextual factors and are framed by the concept of ‘communication 
for social change’.  Elements of this framework include: moving away from people as 
objects for change, towards people and communities as agents for change; moving 
away from delivering messages, towards supporting dialogue and debate on key issues; 
moving away from a focus on individual behaviour, towards a focus on social norms, 
policies, culture and supportive environments; moving away from persuasion, towards 
negotiation and partnership; moving away from external technical expertise, towards 
integrating communities in assessing issues of concern at local level.  
 
Adopting a warm and kind style of interaction with a patient is necessary, but is 
insufficient in itself to effect changes in the adherence behaviours of patients. Tailored 
interventions provide individualised information based upon a specific theoretical 
framework, demographic characteristics or a combination of variables. There is 
evidence that tailored communications are more effective for influencing health 
behaviours than non-tailored materials, and comparisons of stage-tailored versus non-
tailored interventions have shown that tailoring resulted in increased efficacy in 
influencing health behaviours. Identification of stage of change can help determine the 
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most relevant intervention components for each person, thus eliminating the need to 
deliver all intervention components to all patients. The skill of valid measurement to 
assess stage of change provides a foundation for the development of stage-matched 
interventions for the promotion of adherence to medication.  
 
It is important to consider holistic skills that tackle both psychological and physical or 
concrete adherence barriers.  Concrete barriers represent a common set of obstacles to 
adherence, such as the cost of medications, unreliable transportation to make 
appointments, mental health issues and complex treatment regimens. Patients need a 
workable skill or strategy to follow treatment recommendations.  HCPs need to: 
 
 Help overcome practical barriers that make it difficult for patients to effectively 
carry out a course of action.  
 Identify individuals who can provide concrete assistance. Identify resources to 
provide financial aid or discounts.  
 Provide written instructions/reminders. Sign a behavioural contract. Offer links to 
support groups.  
 Provide electronic reminders or follow-up phone calls.  
 
Objective 5: To assess the benefits of the integration of information, motivation and 
behavioural skills needed to practise strict ART adherence in patients receiving ARV 
drugs from Felege Hiwot hospital. 
 
5.2.5 The impact of the integration of information, motivation and behavioural 
skills which were found to be associated with adherence behaviour 
 
The right information when communicated in the right way can bring about the 
appropriate knowledge which results in belief and attitude change which are important 
processes to create the desired motivation. However, information and motivation on 
their own are not enough to achieve perfect adherence. The IMB model posits that 
information and motivation can bring about new behaviour through new skills, i.e., 
knowledge and skill are not enough to result in acceptable practice. Knowledge should 
further grow to belief and belief is the basis for attitude change. Attitude change, in turn, 
results in new and desired practices. The new and desired practices must be shaped 
through the right skills by: 
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 Counselling, educating and training patients 
 Providing regular or continuous training for HCPs 
 
We can achieve the following milestones which are crucial to addressing the 
information, motivation, and behavioural skills mandatory to bring about ART adherence 
behaviour: 
 
 Increase awareness of patients’ need near-perfect adherence level. 
 Assist patients to develop skills to sustain their ART adherence over time for life 
long. 
 Convince the patients that they need to have higher level of adherence to 
medication. 
 Support providers to assess and address adherence barriers: Equip them with 
patient-centred communication skills which facilitate the process of converting 
information to knowledge and knowledge to belief system and attitude change, 
and avail materials integrated into the workflow of provider-patient interaction. 
 
5.3 CONCLUSIONS 
 
Overall the inferential analyses depicted in the figures and tables in chapter 4 show that 
the mediated structural hypothesis of the IMB model of ART adherence is supported 
because the free models analysed together show that motivation and behavioural skills 
are significantly associated with one another and with adherence behaviour as well 
whereas the restricted model analysis shows that one important variable from 
information is strongly and positively associated with adherence behaviour. 
 
Predominantly, adherence-related motivation related significantly and positively to 
behavioural skills, and significantly related positively to optimal adherence. Moreover, 
as predicted by the model, adherence-related behavioural skills were significantly and 
positively associated with optimal adherence.  
 
Though it is not possible to detect strict and direct cause and effect relationships, the 
research showed that information, motivation and behavioural skills are interrelated. 
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Thus, support was provided for the IMB model’s major assertions that adherence-
related information, motivation and behavioural skills are important determinants of 
adherence behaviour and that ART adherence behaviour is influenced by information 
and motivation primarily through their effects on behavioural skills. 
 
Experiences with ART suggest that adherence is arguably the most important issue in 
successfully managing HIV/AIDS. A multifaceted approach to improve adherence is the 
most likely to be beneficial, particularly a combination of actively involving patients in 
their own health care decisions, provision of appropriate supports, multidimensional 
educational programmes that teach behavioural skills to the patient to enhance his or 
her adherence, and tailoring of the regimen to fit the patient.  
 
Furthermore, it is essential that the patient adequately understands the importance of 
adherence and the serious consequences of non-adherence (i.e. treatment failure, or in 
some cases, disease progression, drug-resistance or death). Especially for a condition 
such as HIV, where poor adherence can cause resistance, it may prove wise to delay 
active treatment until the patient understands the demands of the regimen and feels 
truly committed to it. One way in which to gauge a person’s readiness to adhere to a 
regimen, identify specific barriers to adherence, and to simultaneously strengthen the 
patient–provider relationship is to ask the patient an idea of a trial run of the regimen. 
This may be done using vitamin pills or jelly beans, with different tablets or different-
coloured beans representing the various medications. Such a trial can give patients a 
perspective on how dosing schedules and other complexities, such as food restrictions 
or requirements will fit into their daily routine. A trial lasting a few weeks is usually 
sufficient for assessing a patient’s ability to stick to the regimen and overcome the 
barriers. However, such a trial run is unable to mimic possible side-effects. 
 
Ideally, the health practitioner should work together with the patient to select a regimen 
that will fit with his or her lifestyle. If more than one regimen may be appropriate for a 
given patient, providers may want to discuss the regimen, the number of pills, the 
dosing schedule, instructions and potential side effects with the patient. The discussion 
will foster a more collaborative and positive relationship between the practitioner and 
the patient, which is likely to enhance adherence. Once the regimen is decided upon, 
practitioners must make certain that patients fully understand the dosing schedules and 
instructions. 
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Rather than associating doses of medication with times of the day, fitting the regimen to 
the patient’s lifestyle calls for working with the patient to associate medication doses 
with routine activities performed at the times that the medication should be taken. For 
example, morning doses can be associated with morning rituals (e.g. brushing teeth or 
reading the newspaper), and evening doses can be associated with evening routines 
(e.g. children’s homework or watching television news programmes). In general it is 
likely that accomplishing this “fit” will be easier with regimens that require infrequent 
dosing (i.e. once or twice a day). However, the principle of associating medications with 
daily activities can also accommodate more frequent and complex regimens. 
 
The simplest, effective and potent regimen will fail if patients experience side-effects 
that they perceive as problematic and they end up terminating their medications. At the 
time that the regimen is prescribed, health professionals should be proactive and 
provide strategies to help patients manage any side-effects that may occur. Given that 
experiencing side-effects is associated with non-adherence, the provider must 
accurately assess both the patient’s willingness to adhere in the context of possible 
side-effects, and his or her willingness to overcome potential barriers to taking the 
medications as prescribed. 
 
Furthermore, providers and their team members should remain in close contact with the 
patient during early treatment with a new regimen to allow for the timely identification 
and management of all side-effects and toxicities. A further advantage of this approach 
is that it provides an opportunity for reinforcing adherence behaviour. A powerful 
reinforcer of adherence behaviour is positive feedback regarding medication efficacy. 
Consequently, laboratory and other tests should be conducted soon after the initiation of 
treatment to show the extent to which it has been effective. 
 
Health care providers and their teams should address the patient-related factors and 
psychosocial issues associated with non-adherence. While these may vary across 
conditions, screening for active substance abuse and depressed mood would be 
appropriate in many patient groups. Finally, enlisting the support of family members and 
“significant others”, or employing “treatment buddies” (trained community health 
workers) to administer medications can greatly enhance adherence.  A comprehensive 
approach to AIDS care, which includes access to free voluntary tests and counselling, 
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the provision of ART for the prevention of mother-to-child transmission, diagnosis and 
referral of opportunistic infections, social assistance and directly observed provision of 
ART (DOT-ART) can be implemented by using trained health extension workers 
(HEWs) in Ethiopia. 
 
5.4 RECOMMENDATIONS 
 
A number of recommendations emerge from this study, and these are closely linked 
with the conclusions drawn from the data:  
 
(i) Firstly, future research should focus not on the development of new theories but 
rather on the further examination of those already elaborated. Several key 
attributes that should be encompassed by theories explaining behaviour change 
have been suggested, including demonstrated effectiveness in predicting and 
explaining changes in behaviour across a range of domains; an ability to explain 
behaviour using modifiable factors; and an ability to generate clear, testable 
hypotheses. The theories should include non-volitional components (i.e. issues 
over which individuals do not have complete control) for instance, system factors, 
and take into account the influence of external factors, as perceived by 
individuals. 
 
(ii) Secondly, further work is required to identify or develop theories of health 
behaviour that are most applicable to improving adherence to long-term 
medication. Existing health behaviour theories should be tested systematically to 
establish which best predict effects on different kinds of behaviour for different 
groups of people in different contexts. For example, does a particular theory 
predict changes in adherence behaviour for both men and women with HIV in 
both Ethiopia and South Africa? Experimental research and increased clarity in 
theories and methods could assist in the identification of effective behaviour 
change techniques, thereby contributing to the development of evidence-based 
practice in health psychology and implementation research. Similar efforts need 
to be made regarding the use of theories as applied to adherence behaviour. 
 
(iii) Thirdly, the abundance of theories and their poor evidence base highlights the 
need to develop and trial interventions that utilise these theories appropriately 
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(i.e. in concordance with the theory), with well-defined and operationalised 
variables. This will help to advance the study of human adherence behaviour and 
allow for better informed decisions related to how these theories could be more 
widely applied in practice for guidance on developing theoretically informed 
interventions.  
 
(iv) Fourthly, reports of interventions to promote adherence to long-term medications 
for other health issues, such as diabetes, asthma and hypertension, should be 
reviewed to determine how many have drawn on theory in the design and testing 
of these interventions; the range of theories utilised and the ways in which this 
was done; and the ways in which the use of theory contributed to understanding 
the effects of these interventions.  
 
(v) Finally, it is worth mentioning that a recent review found that interventions to 
improve adherence to medication were more effective when they included 
multiple components such as more convenient care, patient education, 
information, counselling, reminders, self-monitoring, self-rewards, reinforcement, 
behavioural skills, social support and telephone follow up. Patients create 
personal representations of health threats and models of the illness and its 
treatment, and it is these that guide their decision-making and behaviour. Thus, 
adherence requires an appropriate model and the right knowledge of the benefits 
of the new targeted behaviour and a belief that the issue requires one’s attention 
and the modification of one’s behaviour. Adherence also requires specific coping 
skills, in addition to behaviour and more convenient care necessary to perform 
the adherence behaviour (WHO 2003:143-146).  With this regard, providers may 
use the 5 A’s Behaviour Change Model (Assess, Advise, Agree, Assist, Arrange) 
which is intended to use for improving chronic illness care (Federal HIV/AIDS 
Prevention and Control Office 2008:64-66; Horizons … 2004:20-104; WHO 
2003:96-103). 
 
Assess: Beliefs, behaviour and knowledge 
 
Advise: Provide specific Information about Health risks and Benefits of change 
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Agree: Collaboratively set goals based on patient’s interest and confidence in their 
ability to change the behaviour. 
 
Assist: Identify personal barriers, strategies, problem-solving techniques and social/ 
environmental support 
 
Arrange: Specify plan for follow-up (e.g., visits, phone calls, mailed reminders) 
 
Specific Interventions after assessment:  
 
 Select strategy: Based on their specific IMB deficits, patients are provided with a 
tailored list of adherence-promoting strategies and asked to select a specific 
strategy to work on. 
 After selecting a strategy, clients are given a list of strategy- specific interventions 
and are asked to select the one that would help them most with taking their HIV 
medications.  
 Clients are encouraged to explore the intervention they choose at their own pace.  
 There are different interventions that address adherence-related IMB deficits. 
 
i. How ARVs work: Explain CD4 cells, viral load (VL), how HIV medication help 
fighting HIV in the body and resistance. 
ii. Explain ARV medication: Discuss dosage, side effects, drugs interactions and 
dietary restrictions for each drugs: 
a. Side-effects and solutions: Explain ARVs side effects and their 
management by patient and providers. 
b. Long-term medication side-effects: Discuss long-term side-effect 
management such as lipodystrophy. 
c. Focus on the fight:  Promote positive attitudes towards one’s HIV 
treatment and share experience of treatment outcomes with other PLHIV. 
d. Positive voices: Share experience with other PLHIV about HIV treatment 
and strategies for overcoming barriers to adherence. 
e. Bill the pill:  Adapt strategies for taking pills that hard to swallow, taste bad 
or nauseous. 
f. Pharmacist education: Discuss about prescriptions and use written 
instructions. 
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g. Match-up-cue for taking medications: Cues daily routines with medication 
taking such as meals. Use calendars, diary and check doses. 
h. Information station: Describe support services available to clients, 
information about counselling and support groups for PLHIV, mental 
health, substance abuse and housing assistance. 
i. Medication reminders: Provide information about use of adherence 
support tools (e.g. alarm, pillbox). 
j. Doctor talk: Discuss with physician about ARVs side effects and 
resistance. 
k. Helping hand: Involve PLHIV in adherence counselling and support for 
other PLHIV. 
l. Medication taking: Fitting medication taking with daily routines. Taking 
medication when one’s routine changes. Taking medication when others 
are around. 
m. Provider-patient communication: Address communication skills with a 
focus on the provider-patient relationship. Present skills of successful 
provider-patient interaction. 
n. Discuss the effect or interaction of street drugs and alcohol with ARVs in 
the body, and give tips for staying healthy and taking ARVs even when 
using drugs or alcohol. 
o. Stress management: Learn about stress and its management. 
p. Battle for health-use tools: Fight off infection, take ARVs at specific time by 
using reminder tools in challenging situations. 
q. Learning from missed doses: Identify reasons for missing doses and 
address accordingly. 
r. Celebrate success: Offered to patients with consistently perfect adherence 
over time. Provide patients a reward certificate and then encourage them 
to learn about maintaining adherence over time. 
 
5.5 CONTRIBUTIONS OF THE STUDY 
 
Findings in this study suggest implications for research and practice. The contributions 
of the study are the following:  
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 Its findings could sensitise programme managers and policy makers to evaluate 
currently practiced strategies and to update them or even change them with new 
ones.  
 The study leaves a room for further research as it has new questions arising from 
the discussion of the findings and that the findings can confidently be 
generalisable to the entire country only if future studies are conducted in different 
districts of the country. 
 
5.6 LIMITATIONS OF THE STUDY 
 
The researcher feels that this study has the following limitations that warrant mention:  
 
(i) First, as the study used cross-sectional design, it did not allow the researcher to 
establish a causal relationship between significantly associated variables and 
treatment adherence, as both variables were measured at the same time. Since 
the study is also a cross-sectional study, it addressed the adherence during only 
the three days prior to the time when the study took place. One therefore needs 
to consider that adherence behaviour might vary among different patients at 
different times and on different days. Another limitation is that a cross sectional 
study of this kind that addresses adherence behaviour in the three days prior to 
the collection of data, may be problematic because it is accepted that adherence 
can vary considerably for different people at different times. Adherence is a 
dynamic process that changes over time with changing beliefs, attitudes, 
emotions, and daily and larger life events. Patients’ adherence decisions are 
continuously renegotiated because changes made to their present medication, or 
introduction of new medicines ‘upset the balance’. Therefore, a more accurate 
set of figures about adherence would be more likely to emerge from a 
longitudinal prospective study than from any cross-sectional studies. The study 
has, however, vigorously strived to show the first clue about the validity for 
potential utility of the IMB model of ART adherence in the ART clients of the 
study health facility. The study findings also afford additional insights and 
extensions in previously reported relationships in the IMB model of ART 
adherence literature. 
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(ii) Secondly, “gold standard” for assessment of adherence does not exist, in this 
study adherence was measured using self-report; studies suggest that self-report 
tends to overestimate adherence and self-reported adherence measurements are 
known to increase adherence rates( Horizons ... 2004:20). This might be one of 
the limitations of this study because the study did not make use of objective 
measures of adherence. The problem with self-reports of health behaviour is that 
they may be influenced by a subject's reluctance to report non-adherence to 
treatment recommendations. Social desirability (projection of a positive image) 
could have induced an overestimation of adherence. Objective measures of 
health behaviour may be reliable if they involve a single observable action such 
as attending a health screening programme but this type of measure becomes 
more difficult, when long-term behaviours are of interest as in a treatment 
regimen for chronic illness. Given the shortcomings of sampling, design and 
measurement related to the IMB already described above, these additional 
problems of measuring behavioural outcome serve only to compound the 
difficulty in assessing the utility and validity of the model. Even when a 
researcher collects data by using a structured questionnaire, there is still the 
possibility that a social desirability bias and recall bias will affect the answers of 
the respondents. This means that the actual adherence rate that the respondents 
have reported might be different if they were to fill the questionnaire by 
themselves while in this case they were asked by their health care providers. 
However, the researcher tried to minimise that by explaining to each patient that 
it was not always easy to adhere to medical treatments in general (Joubert & 
Ehrlich 2007:163). The patients were also informed that their answers would not 
interfere with the care they received. Furthermore, the patients were asked about 
the most recent days. Generally, structured self-report has been reliably 
associated with both objective measures of adherence and viral load (Horizons 
… 2004:9). The study, therefore, supplies important information about the current 
status of the level of optimal adherence behaviour of PLHIV receiving ART care 
at Felege Hiwot hospital. 
 
(iii) Thirdly, the study did not segregate patients into cohorts of treatment (at least 
yearly cohort batches) according to the date of initiation of ART to see issues 
specific to every cohort. For example, forgetfulness to take pills, which was given 
by the majority of the respondents as a reason for missing pills, might be a 
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problem of beginners of treatment until a certain period of time, which can 
improve later as patients stay more on treatment. This could have been 
unreasonably concluded as a main reason if the majority of the participants were 
by chance those who started ART later than the rest. On the other hand, if again 
only a smaller number of the participants were by chance from those who were 
chronically on ART, they could develop “treatment fatigue”, which is not usually 
mentioned and appropriately addressed as a barrier both in the literature as well 
as by the HIV clinicians. As a result, patients were not tightly adherent to their 
medication but this variable, which can be more significant in them, could have 
been masked by other variables predominantly cited by those newer patients 
(Federal MOH and Federal HAPCO 2007:75). However, the researcher believes 
that this was handled by applying random sampling procedure, which provides 
reassurance that the sample is representative of the population of interest so that 
inclusion of every year of cohort of patients in the study can be safely assumed.  
 
(iv) Fourthly, since the study was performed only in one public hospital in Amhara 
and since it was not a longitudinal or a follow-up study, the generalisability of our 
findings may be limited. Whether the study findings would differ in other 
subpopulations of PLWH remains to be determined. As adherence and 
combination therapy are dynamic and continuous process there is a need for 
more research. The study needs to be replicated with a more diverse sample and 
different settings to see if the issues related to adherence are similar across the 
HIV patient population.  
 
(v) Finally, it should also be noted that any understanding of individual health 
behaviour, and interventions to change this, must be located within the relevant 
social, psychological, economic and physical environments. It is clear that poor 
adherence is also the result of factors outside the individual's control, including 
clinic and health care organisation factors. Any focus on changing the behaviours 
of individuals with HIV should not result in the neglect of these other dimensions. 
Interventions that focus on providers, the provider-patient relationship, health 
system and contextual factors therefore also need to be developed and 
evaluated. 
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5.7 CONCLUDING REMARKS 
 
Non-adherence to treatment is a problem of increasing concern to all stakeholders in 
the health system; the extent and consequences of poor adherence have been well 
documented in terms of impact on population health and health expenditure. Poor 
adherence limits the potential of efficacious treatments to improve patients’ health and 
quality of life. This is a particular problem in the context of the chronic conditions that 
currently dominate the burden of illness in today’s society. Across health disciplines, 
providers experience considerable frustration over the high proportion of their patients 
who fail to follow treatment recommendations. 
 
Adherence is a behavioural problem observed in patients, but with causes beyond the 
patient. It occurs in the context of treatment-related demands that the patient must 
attempt to cope with. These demands are characterised by the requirement to learn 
new behaviours, alter daily routines, tolerance in discomforts and inconveniences, and 
persistence in doing so while trying to function effectively in their various life-roles. 
While there is no behavioural magic bullet, there is substantial evidence identifying 
effective strategies for changing behaviour. 
 
Providers often assume that the patient is, or should be, motivated by his or her illness 
to follow a treatment protocol. This means that treatments are frequently offered to 
patients who are not ready to follow them. This reflects an understandable bias towards 
treating the biomedical problem and an under-emphasis on addressing the behavioural 
requirements of the treatment protocol. However, recent research in the behavioural 
sciences reveals this assumption to be erroneous.  
 
First-line interventions to optimise adherence can go beyond the provision of advice. 
Building on a patient’s intrinsic motivation by increasing the perceived importance of 
adherence, and strengthening confidence by intervening at the level of self-
management skills are behavioural treatment targets that must be addressed 
concurrently with biomedical ones if overall effectiveness of treatment is to be improved.  
 
In every situation in which patients are required to administer their own treatment, non-
adherence is likely. Consequently, the risk for non-adherence for all patients should be 
assessed as part of the treatment-planning process and their adherence should be 
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monitored as part of treatment follow-up. The traditional approach has been to wait to 
identify those patients who demonstrate non-adherence and then try to “fix” the 
problem. The risk for non-adherence is ever present. Interventions based on non-
adherence risk-stratification should be offered from the start, as opposed to using a 
stepped-care approach. This approach offers a way of increasing the sophistication of 
the adherence interventions offered to patients. Pharmacists, case managers, health 
educators and others involved in patient care should become familiar with these basic 
concepts.  Providers have an important role to play and an opportunity to dramatically 
improve health by specifically targeting issues of patient adherence. 
 
As such, non-adherence is not simply a “patient “problem.  At the points of initial contact 
and follow-up, providers can have a significant impact by assessing risk and delivering 
interventions to optimise adherence. Poor adherence persists largely because it is a 
complex problem and is resistant to generic approaches to dealing with it. Adherence-
promoting interventions are not consistently implemented in practice because of lack of 
knowledge, lack of incentives, lack of feedback on performance as barriers and 
practitioners report lack of time. To make this way of practice a reality, practitioners 
must have access to specific training in adherence management, and the systems in 
which they work must design and support delivery systems that respect this objective. 
Health care providers can learn to assess the potential for non-adherence, and to detect 
in their patients. They can then use this information to implement brief interventions to 
encourage and support progress towards adherence. Interventions aimed at particular 
diseases need to target the most influential and core determinants among the various 
factors. Given available resources, these targets will invariably be the patient and 
provider, at least in the immediate term. Disease-specific protocols for patients can be 
tailored to their needs. Practitioner protocols can convey the key requirements for the 
creation of optimal treatment relationships and behaviour assessment and management 
skills.  
 
Beyond this, the systems in which providers work must be organised in such a way as 
to enable a consistent and systematic focus on adherence. A major focus for future 
research should be the clarification of the best mode, or modes, of delivering adherence 
interventions. There are many points of contact with patients and times at which such 
interventions are required, and delivering them outside the traditional health system 
may enhance their overall effectiveness. 
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The study findings indicate a need to attend to multiple determinants of ART adherence, 
including information, motivation, and behavioural skills, as critical to sustaining perfect 
adherence over time. An understanding of the dynamics of ART adherence behaviour is 
critical to promote the development, implementation, and evaluation of effective 
behavioural interventions that enhance self-sustained adherence to HIV treatment. The 
current research is a step in that direction, presenting the quantitative test of the 
Information, Motivation, Behavioural Skills model of care initiation and maintenance for 
HIV treatment. In providing the first quantitative evaluation of the IMB model to 
adherence to ART in the current study, the researcher utilised data collected from the 
patient’s perspective to assess the degree to which the IMB model’s core theoretical 
determinants are represented in participant’s response. Specifically, the determinants of 
ART adherence identified by the IMB model of ART adherence (adherence-related 
information, motivation and behavioural skills) were used in a series of structural 
equation model tests to evaluate the fit of the IMB model of adherence to the sample 
data. In doing so, the current study has aimed to evaluate the utility and validity of 
applying the IMB model to a new behavioural and sociocultural setting (i.e., PLWH on 
ART in chronic HIV care clinic at Felege Hiwot referral hospital located in Bahir Dar 
town); identifying the types of theoretical content (i.e., types of information, motivation, 
behavioural skills, which address important cognitive, affective, socio-cultural, and 
environmental contextual factors) underlying adherence to ART to address in future 
intervention development for this target population. 
 
The findings of the current work support the validity and utility of this theoretical model 
in explicating the behavioural factors underlying perfect adherence in HIV treatment for 
the population of PLWH in Bahir Dar town and its surroundings. Specifically, core 
information, motivation, and behavioural skills factors in the model were well 
represented across participants’ experiences.  
 
While multivariate, theory-based models of adherence behaviour are of great interest, 
behaviour change theories and interventions are clearly constrained by a range of 
conceptual and contextual factors. Research is dominated  in understanding why 
individuals fail to adhere, Thus far, exploration of the determinants of ART adherence 
has been dominated by the ‘single-variable’, predictive approach in studying only one or 
a small set of them. In many instances there has been an over-reliance and over-
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investment in such studies with little parallel investment or strategic support being given 
to the development of well-tested, multivariate, conceptual models of ART adherence 
and hence the evaluation of such models is critical in the development of effective 
interventions. In recognition to as a response of this gap, the current study tested one 
such model, the Information, Motivation and Behavioural Skills (IMB) model of ART 
adherence. To this end, the current study findings afford additional insights and 
extensions in previously reported relationships in the IMB model of ART adherence 
literature. For example, information and motivation are not independent entities but are 
interrelated, and the right information when communicated in the right way can bring 
about the appropriate knowledge which results in belief and attitude change which are 
important processes to create the desired motivation. 
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1 
 
Consent form 
 
Client Exit Interview/ Self- administered Questionnaire on Adherence to care for 
HIV/AIDS patients at Felege Hiwot referral hospital in Bahir Dar town 
 
                                                                          Questionnaire Identification   
                                                                             Date of interview    
                                                            Time at the beginning of the interview  
 
Introduction: Hello, Madam/ Sir .My name is (   ).I work for (  ).We 
are conducting a study among clients who come to the health facility of Felege Hiwot 
referral hospital about factors that influence adherence to ART. The information 
collected will help the health institution to improve the quality of ART adherence 
counselling it provides to this health institution and elsewhere. 
 
Confidentiality and informed consent statement: I am going to give a 
questionnaire/ask you questions about your adherence to ART. Your name will not 
appear on this questionnaire and all the information you provide to me will remain 
strictly confidential. You are not obliged to answer any questions that you feel 
uncomfortable with and you can put an end to this interview at any time, if you wish to 
do so. Your participation in this study does not involve any direct risk or benefit to you 
but is very important because your answers, as well as those of other participants will 
help to improve the services offered to you in this health sector and elsewhere. Would 
you like to participate in the study? [YES]  [NO] 
 
Data collector: If the answer is “Yes”, please let the participant sign below to certify that 
the client gave his/her consent to take part in the survey. Otherwise, thank the client, 
conclude the conversation and file the questionnaire. 
       
                                                                                 Signature of the participant 
2 
 
Result Code   
1=Completed 2=Partially Completed 3=Refused 4= Others 
Time at end of Interview/ completing questionnaire   
Checked by -Supervisor Name    
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When using this measure, please cite it as: The LifeWindows Project Team. The LifeWindows 
Information Motivation Behavioral Skills ART Adherence Questionnaire (LW-IMB-AAQ). 2006. 
Center for Health, Intervention, and Prevention. University of Connecticut.  
 
The LifeWindows Information-- Motivation -- Behavioral Skills  
ART Adherence Questionnaire (LW-IMB-AAQ) 
The LW-IMB-AAQ was developed as a measure of barriers to antiretroviral therapy (ART) 
adherence among HIV+ patients in clinical care, following the constructs identified in the 
Information--Motivation--Behavioral Skills (IMB) model of adherence (Fisher, Fisher, Amico, & 
Harman, 2006). The LW-IMB-AAQ was created for use within the LifeWindows adherence 
intervention software program, a computer-delivered ART adherence intervention that is currently 
being evaluated in a multi-site randomized clinical trial1. As such, it is important to note that the 
LW-IMB-AAQ will undergo continued evaluation and revision over the course of the LifeWindows 
project.  
The LW-IMB-AAQ provides the LifeWindows intervention program with critical information 
about users’ ART adherence-related strengths and weaknesses. The software program then uses 
that information to determine which specific intervention activities would be most relevant to a user 
given his or her specific constellation of adherence-related barriers. The user is then offered this 
targeted set of intervention activities and asked to select an activity that would be most helpful in 
improving or maintaining his or her ART adherence. Thus, each LW-IMB-AAQ item serves a dual 
purpose: quantifying information, motivation, and/or behavioral skills strengths and weaknesses, 
and signaling which specific IMB adherence-related deficits should be addressed in order for 
adherence to improve or most effectively be maintained.   
In developing the LW-IMB-AAQ items, item content was targeted specifically to reflect 
barriers within the information, motivation, and behavioral skills constructs pertinent to the 
population involved in the LifeWindows project. It is likely, however, that the barriers reflected in 
the LW-IMB-AAQ will generalize across many HIV+ populations. Nonetheless, any applications of 
this measure outside of the LifeWindows project should take into consideration (a) the purpose for 
which the measure was developed— quantification of IMB based adherence-related deficits so as 
to direct participants to available intervention activities and (b) the target population for whom it 
was developed—HIV+ men and women in clinical care. It is also important to note that the 
measure is not intended for use as a comprehensive or generic measure of the IMB model of 
adherence constructs. Our preliminary analyses suggest that the LW-IMB-AAQ does provide an 
overview of adherence related barriers that generally fall within information, motivation, and 
behavioral skills areas, and can be used as a tool to quickly identify potential adherence related 
deficits in practical or real-world settings. The measure and its psychometric properties will be 
evaluated over the course of the LifeWindows project.  
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The LifeWindows Information-- Motivation -- Behavioral Skills  
ART Adherence Questionnaire (LW-IMB-AAQ) 
ITEMS 
Note: Each LW-IMB-AAQ item represents a barrier primarily falling within the I (Information), M (Motivation), or B 
(Behavioral Skills) constructs. When used with the LifeWindows ART adherence intervention software program, a 
‘critical zone’ is superimposed for a range of response options for each item (reflected here as shaded and in red text). 
Responses within the critical zone are interpreted as signaling the presence of a deficit or potential deficit that then 
triggers the offering of intervention activities specifically developed to address the barrier reflected in the content of the 
item. 
 
I1 I know how each of my current HIV medications is supposed to be taken (for example 
whether or not my current medications can be taken with food, herbal supplements, or 
other prescription medications). 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
 
I2 I know what to do if I miss a dose of any of my HIV medications (for example, whether or 
not to take the pill(s) later). 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
 
I3 Skipping a few of my HIV medications from time to time would not really hurt my health. 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
 
I4 I know what the possible side effects of each of my HIV medications are. 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
 
I5 As long as I am feeling healthy, missing my HIV medications from time to time is OK. 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
 
I6 I understand how each of my HIV medications works in my body to fight HIV. 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
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I7 If I don’t take my HIV medications as prescribed, these kinds of medications may not work 
for me in the future. 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
 
I8 I believe that if I take my HIV medications as prescribed, I will live longer. 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
 
I9  I know how my HIV medications interact with alcohol and street drugs. 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
 
M1 I am worried that other people might realize that I am HIV+ if they see me taking my HIV 
medications. 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
 
M2 I get frustrated taking my HIV medications because I have to plan my life around them. 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
 
M3 I don’t like taking my HIV medications because they remind me that I am HIV+. 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
 
M4 I feel that my healthcare provider takes my needs into account when making 
recommendations about which HIV medications to take. 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
 
M5 Most people who are important to me who know I’m HIV positive support me in taking my 
HIV medications. 
                                         
I strongly 
disagree 
I somewhat 
disagree 
I neither 
agree nor 
disagree 
I somewhat 
agree 
I strongly Agree No one that I 
care about knows 
I am positive 
 
M6 My healthcare provider doesn’t give me enough support when it comes to taking my 
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medications as prescribed. 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
 
M7 It frustrates me to think that I will have to take these HIV medications every day for the 
rest of my life. 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
 
M8 I am worried that the HIV medications I have been prescribed will hurt my health. 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
 
M9 It upsets me that the HIV medications I have been prescribed can affect the way I look. 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
 
M10 It upsets me that the HIV medications I have been prescribed can cause side effects. 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
 
B1 There are times when it is hard for me to take my HIV medications when I drink alcohol or 
use street drugs. 
                                         
I strongly 
disagree 
I somewhat 
disagree 
I neither 
agree nor 
disagree 
I somewhat 
agree 
I strongly agree I don’t drink 
alcohol or use 
street drugs 
 
B2 How hard or easy is it for you to stay informed about HIV treatment? 
                                   
Very hard Hard Sometimes hard, 
sometimes easy 
Easy Very easy 
 
B3 How hard or easy is it for you to get the support you need from others for taking your HIV 
medications (for example, from friends, family, doctor, or pharmacist)? 
                                   
Very hard Hard Sometimes hard, 
sometimes easy 
Easy Very easy 
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B4 How hard or easy is it for you to get your HIV medication refills on time? 
                                   
Very hard Hard Sometimes hard, 
sometimes easy 
Easy Very easy 
 
B5 How hard or easy is it for you to take your HIV medications when you are wrapped up in 
what you are doing? 
                                   
Very hard Hard Sometimes hard, 
sometimes easy 
Easy Very easy 
 
B6 How hard or easy is it for you to manage the side effects of your HIV medications? 
                                   
Very hard Hard Sometimes hard, 
sometimes easy 
Easy Very easy 
 
B7 How hard or easy is it for you to remember to take your HIV medications? 
                                   
Very hard Hard Sometimes hard, 
sometimes easy 
Easy Very easy 
 
B8 How hard or easy is it for you to take your HIV medications because the pills are hard to 
swallow, taste bad, or make you sick to your stomach? 
                                   
Very hard Hard Sometimes hard, 
sometimes easy 
Easy Very easy 
 
B9 How hard or easy is it for you to make your HIV medications part of your daily life? 
                                   
Very hard Hard Sometimes hard, 
sometimes easy 
Easy Very easy 
 
B10 How hard or easy is it for you to take your HIV medications when your usual routine 
changes (for example, when you travel or when you go out with your friends)? 
                                   
Very hard Hard Sometimes hard, 
sometimes easy 
Easy Very easy 
 
B11 How hard or easy is it for you to take your HIV medications when you do not feel good 
emotionally (for example, when you are depressed, sad, angry, or stressed out)? 
                                   
Very hard Hard Sometimes hard, 
sometimes easy 
Easy Very easy 
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B12 How hard or easy is it for you to take your HIV medications when you feel good physically 
and don’t have any symptoms of your HIV disease?  
                                   
Very hard Hard Sometimes hard, 
sometimes easy 
Easy Very easy 
 
 
B13 How hard or easy is it for you to take your HIV medications when you do NOT feel good 
physically?  
                                   
Very hard Hard Sometimes hard, 
sometimes easy 
Easy Very easy 
 
B14 How hard or easy is it for you to talk to your health care provider about your HIV 
medications? 
                                   
Very hard Hard Sometimes hard, 
sometimes easy 
Easy Very easy 
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SCORING LW-IMB-AAQ 
 
IMPORTANT NOTE  
The scoring suggestions provided here are based on our preliminary work with the LW-IMB-AAQ. It 
must be emphasized that the measure is under continued evaluation in the LifeWindows project1 
and may be revised during the course of this multi-site randomized clinical trial. We provide 
suggestions for scale and sub-scale scoring, but strongly encourage all research utilizing this 
measure to carefully explore item covariances, scale structure, reliability, and validity when 
computing scale or sub-scale scores for their specific study populations.   
 
NOT APPLICABLE RESPONSE OPTIONS 
Prior to scoring the LW-IMB-AAQ, M5 and B1’s “not applicable” options must be reviewed. 
Depending on your sample, an M5 response of “No one that I care about knows I am positive” may 
represent a potential barrier (e.g., within the target population HIV disclosure to friends/family is 
common and nondisclosure could impede medication adherence) or may not indicate a potential 
problem (e.g., in the target population disclosure is uncommon and privacy regarding HIV status is 
the ‘cultural norm’). Thus, based on the specific sample targeted, M5’s n/a response might be 
appropriated rescored as ‘strongly disagree’ or ‘strongly agree’. When such determinations are not 
possible, an alternative strategy is to use average scores for motivation and allow this item to be 
missing for those who responded n/a. For B1, participants may indicate n/a because they do not 
use drugs or alcohol. In practice, not applicable responses for B1 may represent the absence of a 
barrier and may be reset to the “strongly disagree” category without consequence.  
 
USE OF EACH INDIVIDUAL ITEM’S CRITICAL ZONES 
Responses within the critical region indicate information, motivation, and/or behavioral skills 
deficits in the content captured by the individual item. Each item can be used individually as an 
indicator for the need for remediation of the deficit specified by the item. This strategy can have 
clinical utility, but it should be noted that because of high inter-item consistency in some of the sub-
scales, multicoliniarity will pose problems in statistical models that attempt to include certain sets of 
items as independent variables. Researches should carefully evaluate that potential when 
assessing models that use individual LW-IMB-AAQ items. Additionally, while the adherence-related 
deficits represented in the LW-IMB-AAQ are likely to be applicable across diverse populations, the 
critical zones developed for the current measure was based on targeted elicitation work with the 
population involved in the LifeWindows project. Thus, it would be prudent for researchers to closely 
evaluate the extent to which the current measure’s critical zones are appropriate for other specific 
study populations.        
 
CREATING SUBSCALES 
Item sets can be used to quantify information, motivation, and behavioral skills strengths, or 
alternatively, weaknesses in regard the ART adherence. It is important to note that the resulting 
subscales are not intended to provide full representation of the IMB model of adherence, but do 
provide a brief measure of the level of informational, motivational, and behavioral skills deficits in 
the targeted population. The scoring strategies presented are based on our preliminary review of 
the LW-IMB-AAQ and primarily utilize a total score strategy (add responses across all items in 
subscale), although, as previously mentioned, an average score strategy could be instead (divide 
the summed responses by the number of valid items for each participant). Because the measure is 
under continued evaluation in the LifeWindows project, the measure and scoring suggestions and 
strategies may change over the course of the multi-site randomized clinical trial.  
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INFORMATION 
Scoring strategies suggested here create a scale that reflects strengths in ART adherence 
Information.  
 
TOTAL SCORE:   
After reverse scoring I3 and I5, sum across all items to create a total score.  
  
ACCURACY SCORE: 
Score only “Strongly Agree” to a value of 1 for all I items except I3 and I5. Set other for 
response values for those items to 0.  
 
Score only “Strongly Disagree” to a value of 1 for items I3 and I5. Set other response values 
for those items are scored 0. 
 
Sum across all items for a ‘total correct’ score. Our current research demonstrates an 
internal consistency for this scale that is expectedly low (.59), as information about diverse 
aspects of one’s ART regimen is not anticipated to be inter-related. According to our 
preliminary analyses, this accuracy score is best represented as a summed total score.  
Alternative strategies may include expanding the range of response options that would 
reflect a “correct” response (e.g., expand from Strongly Agree only to include both Agree 
and Strongly Agree). These alternative strategies are also under evaluation in our on-going 
LifeWindows project. 
 
MOTIVATION 
 SCORING SUBSCALES: 
Items designated with an M are used to quantify the motivation construct and to activate a 
potential motivationally based intervention in the LifeWindows program. Following the IMB 
Model of Adherence (Fisher et al., 2006), adherence-related motivation is comprised of 
personal and social motivation to adhere to one’s regimen. Personal motivation is 
represented as attitudes and beliefs about ART medications and one’s adherence to their 
specific ART regimen across situations and over time. Attitudes/beliefs about ART 
medications themselves are represented by items M9, M10, and M8, which represent the 
perceived consequences of these medications. Attitudes/beliefs about adherence are 
represented by items M1, M2, M3, and M7, each of which speak to the burden of adherence 
and its impact on daily life. Social Motivation is represented primarily by item M5. 
Additionally, items reflecting patient-provider relationship and collaboration (e.g., M4 and 
reverse score of M6) may represent another component of social motivation.  
 
Preliminary data gathered from the LifeWindows project demonstrated an internal item-
consistency of .70 for attitudes/beliefs regarding the burden of adherence (M9, M10, and 
M8) and .75 for attitudes/beliefs about the negative effects of ART medications (M1, M2, 
M3, and M7).  
 
We are currently reviewing the most appropriate combination of the social motivation items. 
Preliminary results suggest a viable combination is summing M4 and M5 and representing 
social motivation as a single indicator item (sum of M4 and M5) or, alternatively, a strategy 
using M5 only as an indicator of social motivation has produced promising results.  
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Other M labeled items may be appropriately considered and combined depending on the 
target sample. Given the dual purpose of each M item (measuring constructs and flagging a 
need for intervention), it is likely that some items will perform better in one versus the other 
function and thus final analyses of the scale may not include all of the M items presented in 
the LW-IMB-AAQ.   
 
TOTAL MOTIVATION SCORE:  
If collapsing across all subscales and creating a total motivation score, where larger values 
reflect larger amounts of motivation towards adherence, items reflecting deficiencies (M1, 
M2, M3, M6, M7, M8, M9, M10) should be reverse scored prior to summing.  
 
BEHAVIORAL SKILLS 
 TOTAL SCORE:   
All B labeled items except B1 can be summed to represent a total behavioral skills score. 
Our preliminary work with LifeWindows project data suggests an internal consistency of .90 
between these items. B1 appears to behave differently and does not share significant 
variability with the other behavioral skills items. B1 may be more valuable as an indicator of 
a barrier and need for intervention, but may also prove to be useful in explaining adherence 
for individuals who specifically use alcohol or drugs. 
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The questionnaire asks about the medications that you may have missed/ took with 
wrong time taking over the last three days 
 
 
 
Instruction: please answer the three questions below. 
 
Note: IF YOU TOOK ONLY A PORTION OF A DOSE ON ONE OR MORE OF THESE 
DAYS, PLEASE REPORT THE DOSE(S) AS BEING MISSED. 
 
 
Normally, how many doses do you take per day? 
 
……………………………………. 
 
How many doses did you miss in the last 72 hours? 
 
…………………………………… 
 
How many doses did you take with delay for > 2 hours in the last 72 hours? 
 
……………………………………. 
